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It has been another wonderful year in the Jefferson Internal Medicine
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CLINICAL IMAGES

Fibrous Web in the Right Atrium: A Complication of
Fungal Endocarditis and Previous Lead Infections
Harry Wang, MD

CASE PRESENTATION
A 57-year-old woman with a past medical history of
severe non-ischemic cardiomyopathy undergoing
orthotopic heart transplant evaluation on milrinone,
prior extraction of multiple pacemaker and implantable
c a rdiove r te r d ef ib rill ato r (I CD) lea ds d u e to
Staphylococcus epidermidis endocarditis, and multiple
central venous catheter infections presented with
several days of worsening dyspnea on exertion,
orthopnea and lower extremity edema, prompting
admission for congestive heart failure exacerbation.

While she received aggressive intravenous diuretics, she
was also found to be febrile to 101.8°F with a white
blood cell count of 11,000/µL. Blood cultures were
drawn, her peripherally inserted central catheter was
removed, and she was started on broad spectrum
antibiotics with imipenem and daptomycin. She
remained hemodynamically stable, but several days into
her hospitalization, her blood cultures grew Candida
albicans. Antibiotics were stopped, and she was
empirically started on anidulafungin. A transesophageal
echocardiogram (TEE) was then performed and showed
linear densities in the right atrium which mimicked the
course of previously extracted leads (Figure 1), consistent
with fibrous sheaths. Also seen was a 5 x 8 mm mobile
vegetation on the ICD lead, multiple linear ‘web-like’
vegetations in the right atrium (Figure 2), and more
typical-appearing vegetations in the superior vena cava
(Figure 3). These findings, in addition to the fungemia,
prompted transvenous ICD extraction, which she
tolerated well. Her subsequent blood cultures were
negative, but given her previous history of lead and line
infections, the decision was made to fit the patient with
a wearable defibrillator and re-evaluate her for infection
in 6 weeks after completion of treatment for fungal
endocarditis. After clearance of infection, her candidacy
for cardiac transplant would also be re-evaluated.

Figure 1: Linear vegetations extending to the coronary sinus and right atrial
appendage. Middle linear echodensity is the current lead.

Figure 2: 3D view on TEE of vegetation on the pacemaker lead with multiple linear
echodensities emanating from the lead.
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Figure 3: TEE showing a large SVC Vegetation extending into the right atrium.

DISCUSSION

REFERENCES

ICD infections often necessitate transvenous lead
extraction to prevent significant mortality; however, in a
minority of cases, intracardiac ‘sheaths’ or ‘casts’ can be
seen on echocardiography after lead extraction.1 ICD
leads can rarely be encapsulated by fibrous sheaths
which grow over time and remain even after lead
extraction. The incidence of residual fibrocalcific tissue is
estimated to be around 8-14%. 2 These sheaths are
postulated to be a potential nidus for endocarditis, and
their presence is associated with a higher risk of death
after lead extraction.3 Clinicians caring for patients with
cardiovascular implantable electronic devices need to be
aware of this entity as their presence may affect further
management. Although they can be detected by TEE, the
entire clinical setting must be carefully examined to
determine which patients with these fibrous sheaths may
have endocarditis and require more diligent follow up.

1. Caiati, C., Pollice, P., Lepera, M. E., Luzzi, G. and Favale, S. An Insight Into The
Etiology Of New Intracardiac Masses (Ghost) After Infected Lead Extraction: A
Single-Center Study Performed By Intracardiac Echocardiography. Journal of
the American College of Cardiology. 2018; 71: 30899-4.
2. Kiuchi, K. et al. The details of an unusual “ghost” after transvenous lead
extraction: Three-dimensional computed tomography analysis. Journal of
Arrhythmia. 2017; 33: 640–642.
3. Narducci, M. L. et al. Presence of ‘ghosts’ and mortality after transvenous lead
extraction. Europace. 2017; 19(3): 432-440.
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CARDIOLOGY

A Case of Left Ventricular Myocardial Calcification
in a Patient with Severe Sepsis
Carly Sedlock, MD, Randi Zukas, MD, and Hillary Landon, MD

INTRODUCTION
Sepsis is an important source of morbidity and mortality
among patients admitted to the Intensive Care Unit (ICU)
and can cause critical damage to all organ systems.
Regarding cardiac complications, sepsis can acutely
result in cardiomyopathy characterized by ventricular
dilatation and a depressed ejection fraction.1 Myocardial
calcification is a more rare, delayed cardiac complication
of severe sepsis that has been reported in literature.1-6
Herein we report a case of a patient with Acute Myeloid
Leukemia (AML) admitted to the TJUH ICU requiring
prolonged vasopressor support for severe sepsis whose
clinical course was complicated by left ventricular
myocardial calcification.

neutropenic fever and a CT chest was repeated which
showed new diffuse myocardial attenuation involving
the left ventricle (Figure 1). A repeat echocardiogram
confirmed calcification of the papillary muscles as well
as persistently decreased left ventricular systolic function
with EF 35-40%.

CASE PRESENTATION
A 56-year-old female with a history of AML status post
7+3 induction chemotherapy, midostaurin and HIDAC
consolidation presented to the emergency department
with acute onset nausea, vomiting, and diarrhea. While
in the ED, the patient was found to be in septic shock
with fever, hypotension, tachycardia and tachypnea.
Physical exam was notable for significant respiratory
distress, altered mental status, diffuse wheezing and
tachycardia with normal heart sounds. Labs were notable
for an acute kidney injury with creatinine 2.6 (baseline
0.6), transaminitis, lactate of 10.5, severe neutropenia,
hemoglobin of 5.8, and platelets of 2,000. The patient
was initiated on broad spectrum antibiotics and
vasopressors, transfused with blood products, intubated
for work of breathing and admitted to the medical
Intensive Care Unit. The patient’s hypotension was
severe and persistent, and was thought to be due to
both septic and cardiogenic shock. Septic shock was
secondary to multifocal pneumonia, typhlitis complicated
by E. coli bacteremia, VRE urinary tract infection, and
CMV viremia; the patient was treated with meropenem,
daptomycin and foscarnet. A TTE revealed new global
hypokinesis with EF 35% and the patient was started on
dobutamine until her hypotension resolved. In the
setting of her shock, the patient’s hospital course was
complicated by acute renal failure requiring temporary
dialysis and vasopressor-induced ischemia with gangrene
requiring bilateral finger transmetacarpal and bilateral
toe transmetatarsal amputations. Weeks later, during the
patient’s prolonged hospital stay, she developed
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Figure 1: CT chest showing LV myocardial calcification.

DISCUSSION
In this paper, we present a patient with AML who
developed left ventricular myocardial calcification several
weeks after a prolonged ICU course requiring high dose
vasopressor support for severe sepsis. While localized
myocardial calcification may often be observed after
myocardial infarction, diffuse myocardial calcification is a
rare, serious complication of septic shock that is usually
discovered, often incidentally on repeat imaging, several
weeks after the patient’s initial presentation. 2,3 Calcium
deposition in cardiac myocytes occurs via metastatic and
dystrophic calcification.1,2 Metastatic calcification results
from disturbances in calcium and phosphate metabolism,
often in the setting of chronic renal failure.1,2 Dystrophic
calcification occurs when calcium deposits into cardiac
myocytes that have undergone necrosis, which occurs
with myocardial infarction, myocarditis, trauma, cardiac
surgery, and severe sepsis.2 Although the exact mechanism

of sepsis-related dystrophic calcification is unclear, it is
proposed that sepsis-induced circulatory changes,
cytokines, and circulating myocardial depressant
substances increase the permeability of cardiac myocyte
membranes to calcium, resulting in calcium influx,
calcium deposition, myofibrillar hypercontraction, and
phosphate depletion; all these changes may cause
mitochondrial dysfunction and myocardial necrosis.1,4,5 In
the setting of sepsis, high levels of catecholamines,
vasopressors given for the treatment of hypotension, and
acidosis also cause injury to cardiac myocyte membranes,
promoting calcium deposition.6
The diagnosis of myocardial calcification is often
discovered incidentally on thoracic CT obtained for
another clinical indication, as occurred in this patient. CT
is a highly sensitive and specific imaging modality for this
diagnosis. 1 , 5 Echocardiogram may show normal
myocardium or increased echodensity of the ventricular
walls, demonstrating calcification; systolic or diastolic
dysfunction may also be observed.1 There are no clear
therapies for prevention or treatment of this cardiac
complication.2

REFERENCES
1. Akbas T, Ozen M, Adiguzel C, Cimsit NC, Karakurt S. Cardiac Calcification
Following Severe Sepsis: A Case Report and Review of the Literature. Anesth
Clin Res. 2014;5(5):409.
2. van Kruijsdijk R, van der Heijden J, Uijlings R, Otterspoor L. Sepsis-Related
Myocardial Calcification. Images Case Reports Hear Fail. 2011;4:e16-e18.
3. Lapatto-Reiniluoto O, Vaalamo M, Takkunen, O MM. Left ventricular
calcification following resuscitation. J Intern Med. 2000;248:85-87.
4. Furman MS, Healey TT, Agarwal S, Grand DJ, Atalay MK. “ Heavy hearted
havoc ” – A case series of petrified myocardium. J Cardiovasc Comput
Tomogr. 2018;12(6):e21-e23.
5. Schellhammer F, Ansen S, Arnold G, Brochhagen HG, Lackner K. Myocardial
Calcification following Septic Shock. Cardiology. 2002;98:102-103.
6. Kapandji N, Redheuil A, Fouret P, Luyt C, Cluzel P, Combes A. Extensive
Myocardial Calcification in Critically Ill Patients. 2018;46(7).

This case highlights a rare but serious and delayed
complication of severe sepsis that should be recognized
by providers caring for critically ill patients. More data is
needed to assess long term clinical consequences of this
phenomenon and interventions for both prevention and
treatment.
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ENDOCRINOLOGY

A Case Report of Pseudohypoglycemia
in a Patient with Leukocytosis
Michael A. Weintraub, MD, Deepika Nandiraju, MD, and Monika Shirodkar MD

INTRODUCTION
Hypoglycemia is most convincingly documented by
Whipple’s triad: low plasma glucose, symptoms of
hypoglycemia and relief of symptoms after treatment.1
Pseudohypoglycemia is a condition where there is an
artifactually low glucose concentration and an absence
of hypoglycemic symptoms. We present a case of
pseudohypoglycemia where leukocytosis played a role
in lowering venous glucose.

CASE DESCRIPTION

CONCLUSION

A 65-year-old male with a history of gout was admitted
for evaluation of hematuria. Labs during his admission
revealed a venous blood glucose of 43mg/dl. Point of
care glucose checks were not ordered on admission as
the patient was not diabetic. The patient was fully alert
and oriented with no somnolence, diaphoresis or
palpitations. He was not taking any antihyperglycemic
medications at home, and he had an HbA1c of 6.2%. He
was hemodynamically stable with no signs of infection.
The only other lab abnormality noted was a leukocytosis
of 95,000/µL. Point of care glucose checks were ordered
with meals and at bedtime. A subsequent venous blood
glucose was 27mg/dL, but the patient remained
asymptomatic and a simultaneous point of care glucose
was 92mg/dL. A close evaluation of the case revealed a
delay between phlebotomy time and processing of the
venous sample. Immediate processing of the following
venous sample revealed a normal glucose (90mg/dL)
that correlated with the simultaneous point of care
glucose. Repeat testing with quick processing of the
sample clarified that the measurements of low venous
blood glucose levels were due to in vitro glucose
consumption by leukocytes that occurred between the
times of phlebotomy and sample analysis.

DISCUSSION
Pseudohypoglycemia is not a clinical syndrome, but
rather a reflection of ar tifactually low glucose
concentration. Although there are case reports in the
literature, this phenomenon is under-recognized among
health care professionals. Causes of pseudohypoglycemia
differ based on the method of glucose measurement. 2
Low capillary blood glucose is seen with decreased
perfusion because decreased perfusion leads to increased
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glucose uptake by peripheral tissues. Some common
clinical examples include patients with peripheral
vasoconstriction in hypovolemic shock, Raynaud’s disease
and peripheral vascular disease. In contrast, low venous
blood glucose levels can be observed in leukemia or
polycythemia vera where high nucleated cell counts
cause increased glycolysis.3,4 Waldenstrom macroglobulinemia has also been reported to generate falsely low
venous blood glucose readings due to interference of the
proteins with the lab result.5

5

Pseudohypoglycemia should be considered in
asymptomatic patients with low blood glucose levels
before initiating an extensive work up.

REFERENCES
1. Lee KT, Abadir PM. Failure of Glucose Monitoring in an Individual with
Pseudohypoglycemia. Journal of the American Geriatrics Society. 2015
Aug;63(8):1706-8.
2. Pitkin AD, Rice MJ. Challenges to Glycemic Measurement in the Perioperative
and Critically Ill Patient: A Review. Journal of diabetes science and
technology. 2009 Nov;3(6):1270-81.
3. Assaad SN, Vassilopoulou-Sellin R, Samaan NA. Pseudohypoglycemia in
chronic leukemia. Tex Med. 1988 Jul;84(7):36-7.
4. Farfel Z, Freimark D, Mayan H, Gafni J. Spurious hypoglycemia, hyperkalemia
and hypoxemia in chronic hemolytic anemia. Isr J Med Sci. 1990
Nov;26(11):606-10.
5. Tarasova VD, Zena M, Rendell M. Artifactual Hypoglycemia: An Old Term for
a New Classification: Table 1. Diabetes Care. 2014 May;37(5):e86.

ENDOCRINOLOGY

Thyrotoxic Periodic Paralysis – A Case Report of a
Rare Cause of Paralysis in a 39-Year-Old Asian Man
R. Benson Jones Jr, MD, and James Uricheck, MD

INTRODUCTION
Uncontrolled hyper thyroidism has a myriad of
presentations. Classically, symptoms include weight loss,
tremor, palpitations, shortness of breath, diarrhea, anxiety,
and heat intolerance. A rare manifestation of hyperthyroidism is thyrotoxic periodic paralysis (TPP). Periodic
paralysis is a musculoskeletal channelopathy manifested
by episodes of painless muscle weakness often
precipitated by heav y exercise, fasting, or high
carbohydrate meals. Although classically associated with
painless weakness; cramping, myalgias, and stiffness can
also occur prior to the episodes as prodromal symptoms.
Neurologic examination during an attack typically
demonstrates proximal more than distal muscle
weakness, and the upper extremities are more commonly
affected than the lower extremities.1-4 Consciousness and
sensation are preserved, and respiratory muscle
involvement is exceedingly rare. Episodes of weakness
can last from a few hours up to 72 hours with intermittent
recovery between attacks. Patients most often have
diminished deep tendon reflexes, but reflexes may be
preserved in some cases. We present a case of TPP,
discuss the differential diagnosis of periodic paralysis, and
review the pathophysiology and management of TPP.

CASE DESCRIPTION
A 39-year-old man with a past medical history of
hyperthyroidism presented with 5 days of progressive,
bilateral leg weakness and neck pain. On the day of
presentation, the patient was unable to walk normally. He
reported a 40-pound weight loss over the 3 months prior
to admission. He had been diagnosed with a “thyroid
problem” five years ago in Taiwan after having a similar
episode, but he had stopped taking the prescribed
medication when he arrived in the United States two
years ago. He never received radioactive iodine. He
endorsed palpitations, dizziness, headache, and
diaphoresis. He denied chest pain, shortness of breath,
nausea, vomiting, and diarrhea. On exam, he was
diaphoretic, but awake, alert and oriented without
distress. His pupils were equal, round, and reactive
without lid lag or proptosis, although, on repeat
examination there was concern for lid retraction in the
left eye. There was mild thyromegaly and he was
tachycardic with a grade 2/6 holosystolic murmur loudest
in the left sternal border. He had no sensory deficits, but

2/5 strength in hip and knee flexion and extension
bilaterally, and 3/5 strength in plantar flexion and
extension bilaterally. ECG showed sinus tachycardia at a
rate of 106 beats per minute with bigeminy and
nonspecific T wave changes. Labs notable for a potassium
of 1.7 mmol/L (reference range 3.4-4.5 mmol/L),
magnesium of 1.3 mEq/L (reference range 1.3 – 2.1
mEq/L), thyrotropin <0.02 mIU/L (reference range 2.5-4.5
mIU/L), free T4 >7.8 ng/dL (reference range 0.7 – 1.7 ng/
dL), and free T3 of 23.3 pg/mL (reference range 2.0 – 4.4
pg/mL). CT scan of the orbits without the administration
of intravenous contrast showed no extraocular muscle
involvement or proptosis. Ultrasound of the thyroid
showed heterogenous texture and innumerable nodules
in both lobes suggestive of thyroiditis.
Endocrinology was consulted for hyperthyroidism, and
recommended methimazole 30mg daily in addition to
potassium replacement and propranolol 40mg.
Ophthalmology was consulted and there was no
evidence of thyroid optic neuropathy, but they did
comment on possible lid retraction in the left eye and
enophthalmos in the right eye. The patient was admitted
to the ICU for frequent laboratory checks and close
monitoring. About 6 hours following potassium
replacement, antithyroid therapy and beta blockade, the
patient’s strength and potassium improved.

DIFFERENTIAL DIAGNOSIS
Causes of potassium loss can be classified as renal or
nonrenal, or separately by transcellular shift, one of the
causes of which is periodic paralysis. Causes of periodic
paralysis include hyperkalemia, hypokalemia, familial
hypokalemic periodic paralysis, or Andersen syndrome,
an autosomal dominant inherited defect of the inward
rectifying potassium channel associated with short
stature, hypertelorism, clinodactyly, and micrognathia.5

OUTCOME AND FOLLOW UP
Following potassium replacement, the patient was
discharged on methimazole 30mg daily without any
neurologic symptoms. Despite having been scheduled
for an appointment with Endocrinology, the patient was
lost to follow-up.
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DISCUSSION

KEY POINTS

TPP is a rare, potentially life-threatening complication of
hyperthyroidism. TPP occurs in about two percent of
Asian patients with hyperthyroidism compared to 0.1 to
0.2 percent of the general population.3 Despite the fact
that hyperthyroidism occurs more frequently in women,
over 95% of TPP cases occur in men.6 Disease onset
typically occurs between ages 20 and 50 years, whereas
familial hypokalemic periodic paralysis and Andersen
syndrome occur in patients typically under the age of 20
years. 7- 8 The pathophysiology of TPP relates to
hypokalemia: thyroid hormone increases sodiumpotassium ATPase activity on skeletal muscle, forcing
potassium to the intracellular space. The resultant
hyperpolarized muscle membrane reduces the
excitability of the muscle tissue. Excess thyroid hormone
also increases insulin resistance and beta-adrenergic
responsiveness. Insulin and epinephrine both enhance
sodium-potassium ATPase activity, further forcing
potassium into the cell.7-8

Thyrotoxic periodic paralysis is a rare complication of
hyperthyroidism consisting of painless muscle weakness
and hypokalemia. Acute management involves
potassium replacement and propranolol, while long
term prevention requires methimazole to maintain
euthyroid status.

The management of TPP consists of potassium repletion
and normalization of thyroid hormone. Patients are
typically hospitalized and monitored on telemetry due to
the risk of cardiac arrhythmias in the setting of labile
potassium levels. Correction of potassium provides the
mainstay of treatment, and it is important to check
potassium levels frequently due to the risk of rebound
hyperkalemia.9 Intravenous potassium provides more
rapid normalization of potassium levels and is the
recommended treatment modality. 10 As always with
hypokalemic patients, concurrent repletion of hypomagnesemia, if present, is recommended as well. For patients
who are found to be refractory to potassium repletion
monotherapy or who are deemed to be at high risk of
complications due to arrhythmia, concurrent therapy
with propranolol, methimazole, or both may be utilized
as well. Preventative therapy requires proper monitoring
of TSH with the goal of sustaining a euthyroid state with
methimazole. Empiric potassium repletion has not been
shown to be an effective deterrent.7

12 | The Medicine Forum, Volume 20

5

REFERENCES
1. Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases
and review of the literature. Medicine (Baltimore). 1992;71(3):109-20.
2. Kelley DE, Gharib H, Kennedy FP, Duda RJ, Mcmanis PG. Thyrotoxic periodic
paralysis. Report of 10 cases and review of electromyographic findings. Arch
Intern Med. 1989;149(11):2597-600.
3. Hsieh MJ, Lyu RK, Chang WN, et al. Hypokalemic thyrotoxic periodic
paralysis: clinical characteristics and predictors of recurrent paralytic attacks.
Eur J Neurol. 2008;15(6):559-64.
4. Hsieh, Susan. “A Unique Presentation of Thyrotoxic Hyookalemic Periodic
Paralysis.” Proceedings of UCLA Healthcare, 2014, proceedings.med.ucla.
edu/wp-content/uploads/2016/11/A-Unique-Presentation-of-ThyrotoxicHypokalemic-Periodic-Paralysis_CB_Edited.pdf.
5. Sansone V, Griggs RC, Meola G, et al. Andersen's syndrome: a distinct
periodic paralysis. Ann Neurol. 1997;42(3):305-12.
6. Rhee EP, Scott JA, Dighe AS. Case records of the Massachusetts General
Hospital. Case 4-2012. A 37-year-old man with muscle pain, weakness, and
weight loss. N Engl J Med. 2012;366(6):553-60.
7. Annie W. C. Kung; Thyrotoxic Periodic Paralysis: A Diagnostic Challenge, The
Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 7, 1 July
2006, Pages 2490–2495.
8. Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80(1):99-105.
9. Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features
of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med.
1999;159(6):601-6.
10. Cesur M, Bayram F, Temel MA, et al. Thyrotoxic hypokalaemic periodic
paralysis in a Turkish population: three new case reports and analysis of the
case series. Clin Endocrinol (Oxf). 2008;68(1):143-52.

GASTROENTEROLOGY & HEPATOLOGY

Sealing the Diagnosis of Celiac Disease in Pregnancy
Ritu Nahar, MD and Avani Amin, MD

INTRODUCTION
Celiac disease (CD) is an immune mediated condition
that results from a reaction to dietary gluten and primarily
affects the small intestine. Genetically predisposed
individuals develop a chronic inflammatory state of the
small intestine which leads to malabsorption. The disease
is mediated by HLA DQ2 or DQ8 haplotypes, which bind
the gliadin peptides of gluten, present the peptides to
CD4+ T lymphocytes and trigger cytokine and B
lymphocyte responses.1
The prevalence of CD in the United States is approximately
1% and can reach up to 4-5% in at-risk groups.2 Serologic
study of asymptomatic elderly patients in the United
Kingdom revealed a 1% prevalence rate of CD. The
diagnosis of CD can be challenging in those without the
classic malabsorptive symptoms of chronic diarrhea and
bloating. Patients with silent CD vary in their presentation.
In some cases, the diagnosis is made after a patient
presents with iron deficiency anemia, osteoporosis, or an
incidental finding of duodenal villous atrophy on
endoscopy.3,4 Additionally, undiagnosed CD can increase
long term risk of lymphoma, infertility, miscarriage, and
complications in pregnancy.5,6 Mothers with untreated
active CD are at higher risk of preterm labor, small for
gestational age, or low birthweight infants.6 This case
reinforces the importance of recognizing atypical
presentations of CD in pregnancy to prevent maternal
and fetal complications due to active disease.

CASE PRESENTATION
A 28-year-old G1P0 female of Italian and Irish descent
with no prior medical history presented to her obstetrician
at 15 weeks gestation with asymptomatic hypertension
and transaminase elevation. Pertinent physical exam
findings included gravid abdomen and trace pitting
edema of the lower extremities. Laboratory data were
significant for AST and ALT of 52 and 42, respectively.
These values increased to AST and ALT of 221 and 203
at 30 weeks gestation and remained in the 100-200
range for the remainder of her pregnancy.
The differential diagnosis for the patient’s transaminase
elevation included pre-eclampsia, HELLP syndrome,
intrahepatic cholestasis of pregnancy, acute fatty liver of
pregnancy, autoimmune hepatitis, Wilson's Disease, CD,
hereditary hemochromatosis, and nonalcoholic fatty
liver disease. Initial workup for transaminase elevation
was remarkable only for hepatic steatosis on abdominal
ultrasound, with normal liver size, echogenicity and
echotexture. Iron studies were consistent with iron

deficiency anemia. Serologic testing for etiologies of
transaminase elevation including hepatitis A, hepatitis B,
hepatitis C, auto-immune hepatitis, primary biliary
cholangitis, Wilson’s disease, and alpha-1 anti-trypsin
deficiency were unremarkable. The patient was
diagnosed with chronic hypertension and transaminase
elevation secondary to superimposed preeclampsia. She
delivered a 2850 gram female at gestational age of
37w1d. The patient’s transaminases remained elevated
up to three times the upper limit of normal post-partum
which prompted re-evaluation. In addition to repeat
testing for the aforementioned viral, auto-immune, and
inherited causes of transaminase elevation, a Celiac
antibody panel including endomysial antibody IgA,
anti-tissue transglutaminase antibody (IgA tTG), and
immunoglobulins was checked. She was ultimately
found to have weakly IgA tTG of 6 units/mL (upper limit
of n o r m a l is 3 ). B i o ps y at t h e t i m e of
esophagogastroduodenoscopy (EGD) revealed
duodenal mucosa with intraepithelial lymphocytosis and
focal moderate villous blunting which met Marsh 3b
criteria for CD. She was started on a gluten free diet with
subsequent normalization of her transaminase levels.

DISCUSSION
There is an established connection between active CD
and potential reproductive health repercussions including
unexplained infertility, miscarriage, fetal growth restriction,
delayed menarche, early menopause and secondary
amenorrhea.7-13 Adherence to a strict gluten free diet has
also been shown to curtail risk of fetal growth restriction,
infertility and miscarriage. 14 There are two leading
hypotheses for the pathogenesis of adverse pregnancy
outcomes in CD. One hypothesis is an antibody mediated
process inferred by the close link between CD activity and
reproductive failure. Potential mechanistic models have
been proposed based on in vitro studies. The first is direct
binding of anti-TG antibodies to trophoblasts of the
embryo resulting in apoptosis and impaired trophoblast
invasion.15 The second is anti-tTG antibodies inhibiting
maternal endometrial angiogenesis by impairing the
cytoskeleton structure of endometrial endothelial cells.16
Another hypothesis is based on an association between
an increased rate of spontaneous abortion and certain
vitamin and mineral deficiencies which have increased
prevalence in CD.
Pregnancy and the postpartum period have a profound
effect on autoimmune disorders transcending CD. The
mechanism driving this is unclear. It has been proposed
that pregnancy causes dysregulation of certain populations
The Medicine Forum, Volume 20 | 13 5

of T-helper cells to allow for tolerance of paternal antigens
introduced by the fetus. This is mediated by an increase in
T-helper 2 type cells (Th2) over T-helper 1 type cells (Th1).
Autoimmune diseases that are predominately Th1
regulated can improve in pregnancy, while those that are
Th2 mediated may be exacerbated. 21 Celiac disease is a
Th1 mediated disease, therefore pregnancy may make
detecting antibodies and successfully diagnosing the
disease more challenging.22
Given the implications of CD in several obstetric and
gynecologic disorders, it’s imperative to address how and
who should be tested. The gold standard for diagnosing
CD includes positive serology confirmed by duodenal
biopsy via an upper gastrointestinal endoscopy. The
spectrum of histological changes seen in the small
intestinal architecture are categorized using Marsh’s classification system. 23 However, given the risks of sedation,
pregnancy is a relative contraindication to endoscopy.
Thus, screening for celiac disease antepartum would
occur with serological tests with postpartum endoscopy
to confirm the diagnosis.
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GASTROENTEROLOGY & HEPATOLOGY

Complicated Persistent Peritonitis
Lindsay Roth, BA and Kumar Sarkar, MD

INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is a common
complication of end-stage liver disease. SBP can present
with many symptoms such as abdominal pain, fever and
altered mental status.1 The diagnosis of SBP is made
when ascitic fluid from a paracentesis has an absolute
neutrophil count (ANC) more than 250/uL, there is a
positive ascitic fluid culture, and no secondary source of
infection can be idenitifed. 2 However, nearly 60% of
patients with SBP have negative fluid cultures. 3 These
patients can still potentially have SBP and should be
treated as such since in-hospital mortality ranges from
20-40%.1,4 Conventional treatment for SBP includes a
third-generation cephalosporin for five days, followed
by lifetime prophylaxis most commonly with a fluoroquinolone. 5 After 48 hours of antibiotic treatment, a
repeat paracentesis should be performed. If the ANC
does not decrease by at least 25%, it is considered a
therapeutic failure and the antibiotic should be changed.5
With early diagnosis and appropriate antibiotic regimen,
SBP is treatable.
When therapy for SBP fails and the ascitic fluid ANC
remains elevated, the peritonitis is considered persistent.
Persistent peritonitis should raise suspicion for a
secondary cause. An increase or lack of a significant
decrease in the ANC in follow-up paracentesis should

provoke a full work-up for secondary causes of
peritonitis.1 Secondary causes include intra-abdominal
abscess, bowel perforation, bile leak and malignancy. If
a source is not found, persistent peritonitis should be
treated with broad-spectrum antibiotics and/or
antifungals early on.6 Furthermore, patients with a history
of an ICU stay during the previous three months,
antibiotic treatment during the previous three months,
or a recent intervention in the hospital setting tend to be
at higher risk for persistent, difficult to treat peritonitis.7
This includes resistance to third-generation cephalosporins and quinolones, which has been documented in
40-50% of difficult to treat peritonitis cases.7 When
patients have complications in their hospital course,
difficult to treat peritonitis should be of concern.

CASE PRESENTATION
A 63-year-old transgender female with a two year history
of decompensated NASH cirrhosis complicated by
portal hypertension, esophageal variceal bleeding status
post banding nine months prior, portal vein thrombosis,
hepatic encephalopathy, COPD, sarcoidosis, anxiety and
depression presented to a local hospital with septic
shock secondary to cholangitis. The patient presented
with fatigue, epigastric pain/distension and was
hypotensive (80s/40s mmHg) despite fluid resuscitation.

Figure 1. Paracentesis Results and Antibiotic Course
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Labs were notable for a leukocytosis (23 x 10^9/L),
thrombocytopenia (36 x 10^9/L), hyperbilirubinemia
(total bilirubin 8.1 mg/dL), lactic acidosis (lactate 6.7
mmol/L), renal failure (creatinine 2.56 mg/dL), and a
MELD score of 37. The patient was started on vasopressors
and broad-spectrum antibiotics. On imaging, the
common bile duct was dilated to 19 millimeters with
obstructing stones consistent for choledocholithiasis.
She underwent endoscopic retrograde cholangiopancreatography (ERCP) with bile duct stenting and was
started on Piperacillin-Tazobactam. After the procedure,
she remained intubated for two days due to acute
hypoxic respiratory failure. A day after extubation, she
began to experience worsening abdominal distension
and shortness of breath and therefore underwent large
volume paracentesis, which was negative for SBP. Her
liver function tests and total bilirubin continued to
increase, so she underwent repeat ERCP and sphincterotomy with removal of a stone and the previously
placed biliary stent.
Despite an eight-day course of Piperacillin-Tazobactam,
followed by a three-day course of Levofloxacin for
cholangitis, the patient underwent a therapeutic
paracentesis and the ANC was found to be elevated to
1,081/uL with negative cultures. She was started on
Meropenem for SBP. She continued to have multiple
therapeutic paracenteses, with persistently elevated
ANCs despite antibiotic therapy (Figures 1 and 2). Cultures
of the ascitic fluid remained negative through the entire
course of peritonitis. Due to the persistently elevated
ANCs, antifungal coverage with Anidulafungin was

Figure 2. Timeline of Antibiotics and Paracentesis Results
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started as well. Through discussion with the infectious
disease team, it was eventually decided to observe the
patient off antibiotics and antifungal therapy in an effort
to prevent intra-abdominal colonization of multidrug
resistant organisms. However, while off antibiotics, she
continued to have an elevated ANC without any culture
growth and was therefore restarted on Meropenem and
Anidulafungin. After five days of antibiotics, repeat
paracentesis was finally negative for SBP. Her antibiotics
were switched to Ciprofloxacin for SBP prophylaxis. After
four days on the prophylactic antibiotic, a repeat
paracentesis revealed an elevated ANC consistent with
SBP. However, since the patient did not appear clinically
infected, she was continued on prophylactic
Ciprofloxacin. Unfortunately, a day later, the patient
developed a pruritic rash on her trunk and legs consistent
with a drug rash due to the Ciprofloxacin. Therefore, SBP
prophylaxis was switched to Cefuroxime and repeat
paracentesis was negative for SBP.
The patient did undergo a full work-up during her
prolonged hospital course to rule out secondary causes
of peritonitis. A CT scan of her abdomen and pelvis did
not identify an intra-abdominal abscess or bowel
perforation. Abdominal ultrasound was negative for a
bile leak and testicular ultrasound was negative for
testicular torsion or epididymitis. A HIDA scan was
negative for cholecystitis and ascitic fluid cytology was
negative for malignancy. Fortunately, the patient was
able to be re-listed on the liver transplant list following
clearance of the infection and she successfully
underwent liver transplant shortly thereafter.

DISCUSSION

REFERENCES

The diagnosis of SBP is made when paracentesis fluid
analysis has an ANC of more than 250/ uL, a positive fluid
culture and no secondary source of an intra-abdominal
infection.2 While our patient fulfilled two of these criteria,
she also had multiple risk factors for difficult to treat
peritonitis. Some of the risk factors for difficult to treat
peritonitis include an ICU admission during the previous
three months, antibiotic treatment during the previous
three months, and a recent intervention in the hospital
setting, all of which our patient had.7

1. Rimola A, Garcia-Tsao G, Navasa M, Piddock L, Planas R, Bernard B. Diagnosis,
treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus
document. J Hepatol. 2000; 32:142-153.

Management of persistent peritonitis should include an
extensive work-up for secondary peritonitis. 1 Once a
secondary cause is ruled out, persistent peritonitis should
be approached by broadening antibiotics and starting an
antifungal.6 However, this can lead to development of
multidrug resistant organisms. Further research is needed
on treatment for persistent peritonitis to develop definitive
management, while considering multidrug resistant
organisms.

2. Such J, Runyon BA. Spontaneous Bacterial Peritonitis. Clin Infect Dis. 1998;
27:669-674.
3. Nobre SR, Cabral JEP, Gomes JJF, Leitão MC. In-hospital mortality in
spontaneous bacterial peritonitis: A new predictive model. Eur J Gastroenterol
Hepatol. 2008; 20(12):1176-1181. doi:10.1097/MEG.0b013e32830607a2.
4. Thuluvath PJ, Morss S, Thompson R. Spontaneous bacterial peritonitis—
in-hospital mortality, predictors of survival, and health care costs from 1988 to
1998. Am J Gastroenterol. 2001; 96:1232–1236.
5. Alaniz C, RE R. Spontaneous bacterial peritonitis: a review of treatment
options. P&T A Peer-Reviewed J Manag Care Formul Manag. 2009;
34(4):204-213.
6. Desai AP, Reau N, Reddy KG, et al. Persistent spontaneous bacterial peritonitis:
A common complication in patients with spontaneous bacterial peritonitis
and a high score in the model for end-stage liver disease. Therap Adv
Gastroenterol. 2012; 5(5):275-283.
7. Shalimar SKA. Difficult to treat spontaneous bacterial peritonitis. Trop
Gastroenterol. 2013; 34(1):7-13.

The Medicine Forum, Volume 20 | 17 5

HEMATOLOGY & ONCOLOGY

Bilateral Choroidal Metastases as Initial Presentation
of Widespread Follicular Thyroid Cancer
Jennifer Hong, MD

Figure 1.

Figure 2.

INTRODUCTION

left eye vision loss and eventual right eye vision changes.
Lung examination revealed fine inspiratory crackles.
Thyromegaly with a discrete 3 cm palpable thyroid
nodule was noted on examination. He was clinically
euthyroid.

Follicular thyroid cancer (FTC) is the second most
common malignancy of the thyroid gland and comprise
10-15% of all thyroid tumors; the usual mode of spread is
via hematogenous dissemination with the most common
sites of metastases being the lungs and bones.4 A case is
presented to demonstrate the unusual presentation of
follicular thyroid cancer as bilateral choroidal metastases.
Although exceptional, a diagnosis of choroidal
metastases should be considered in any decline in visual
acuity in patients with thyroid cancer.

CASE PRESENTATION
A 54-year-old male with a history of congenital left ear
deafness, mitral valve prolapse, and right temporal
hemangioma status post resection presented with a
chief complaint of progressive visual changes and
shortness of breath. The patient reported a two-month
history of gradual nonproductive dry cough, which
progressed to dyspnea on exertion and later at rest. He
was initially diagnosed with atypical pneumonia by his
primary care physician, but after a course of treatment
with Doxycycline and Prednisone, he found no relief.
Additionally, he gave a history of periorbital eye pain with
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Chest x-ray revealed reticulonodular opacities in both
lungs, concerning for multifocal pneumonia. Fine-needle
aspiration of the thyroid revealed atypical follicular cells
suspicious for neoplasm (figure 1). CT chest revealed
innumerable pulmonary nodules, enlarged necrotic
mediastinal nodes, and lytic lesions within the right
lateral sixth rib and T3 vertebral body (figure 2). He was
evaluated by ophthalmology for visual impairment and
was diagnosed with bilateral intraocular choroidal lesions
with retinal detachment.

OUTCOME AND FOLLOW-UP
The physical examination and radiographic findings in this
patient were highly concerning for a metastatic
malignancy. The fine-needle aspiration biopsy was
suspicious for a thyroid primary tumor, however, the
unlikelihood of follicular thyroid cancer to metastasize to
include bilateral globes and diffuse pulmonary involvement
put the diagnosis into question. Given the unclear clinical

picture, he underwent an endobronchial ultrasound
biopsy of mediastinal lymph nodes for a definitive
diagnosis which indeed revealed metastatic thyroid
carcinoma. In the interim, his deteriorating visual acuity
warranted emergent palliative radiation to bilateral globes
to prevent worsening of his vision, consisting of 20 Gy in
5 fractions. Additionally, his course was complicated by
episodes of perioral numbness and tingling, tongue
weakness, and headaches. CT and MRI imaging of the
brain revealed two enhancing parenchymal lesions, most
consistent with metastases, and several extracranial
metastases, including orbital wall and globes for which he
underwent whole brain radiation.
A multidisciplinary team involving Medical Oncology,
Endocrinology, Radiation Oncology, Neurosurgery, and
Otolaryngology was involved in shared decision making
for the patient. He was initiated on standard of care for
metastatic follicular thyroid carcinoma. The patient
underwent a total thyroidectomy with central neck
dissection. Post-operatively he was initiated on T3
Cytomel, Calcitriol, and Calcium carbonate to maintain
hormone levels. At the time of his most recent follow-up,
the patient was planned for radioactive iodine ablation.

DISCUSSION
Follicular thyroid cancers account for 10-15% of all
thyroid tumors. The peak incidence is in the 4th and 5th
decade with a female predominance.7 Many cases are
subclinical. Follicular thyroid cancers come to medical
attention after finding a thyroid nodule on physical
examination or incidentally by radiographic workup.
While fine-needle aspiration is often the initial diagnostic
next step in the evaluation of a thyroid nodule, it cannot
distinguish follicular cancers from follicular adenoma. A
fine-needle aspiration cytology report of "suspicious for
follicular neoplasm" will prove to be benign follicular
adenoma in 80% of cases. 3 For this reason, surgical
resection of the thyroid gland is necessary for histologic
demonstration of tumor extension beyond capsule or
vascular invasion.
The usual mode of dissemination is via the hematogenous
route. About 15% of patients with follicular thyroid cancer
have metastases beyond the cervical or mediastinal
margins on initial presentation or it may occur as a
delayed presentation following initial treatment.7 In
patients whom a metastatic disease was diagnosed at
initial presentation, the predominant metastatic sites
were the lungs (49%), bones (25%) both lungs and bones
(15%), and lastly CNS and other soft tissues (10%).
Choroidal metastases secondary to follicular thyroid
cancer is rare. When present, it often occurs in patients
with advanced disease portending a poor prognosis.6
Fewer cases of bilateral choroidal involvement are
reported in the literature. The choroid is a vascular

pigmented layer of tissue between the sclera and retina
whose blood flow is ample.1 The mainstay of diagnosis
of choroidal metastases is by history and ophthalmologic
assessment. Choroidal metastases can be asymptomatic
or present with varying symptoms depending on the
location. Decreased or blurred vision along with eye pain
is a common symptom if choroidal metastases involve
the optic nerve or macula. If associated with underlying
retinal detachment, it can present with flashing lights
and floaters. 2 By the time of ocular involvement, most
patients have evidence of widely disseminated metastatic
disease as with this patient.8
Current National Comprehensive Cancer Network
guidelines recommend total thyroidectomy as the initial
step if metastatic disease is apparent at the time of
diagnosis of follicular thyroid carcinoma followed by
post-operative use of radioactive iodine ablation.5 The
rationale for this approach is for optimal uptake of
radioactive material in residual tissue without competition
from the thyroid gland. In this case, the demonstration
of the highly proliferative nature and widespread burden
of the patient's tumor portended a poor prognosis.
Distant metastases are the principal cause of death from
follicular thyroid cancers. While bilateral choroidal
metastases are a relatively rare condition, further studies
should identify this unique patient population for further
characterization.
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Worsening Autoimmune Neutropenia After Stopping
Ibrutinib in a Patient With Chronic Lymphocytic
Leukemia: Case Report and Review of Literature
Natalie Rosen, BA, Thomas Klumpp, MD, and Sameh Gaballa, MD, MSc

INTRODUCTION
Autoimmune cytopenia (AIC) is relatively common in
patients with chronic lymphocytic leukemia occurring
in 5-10% of patients during the course of their disease.1
Autoimmune hemolytic anemia (AIHA) constitutes the
highest prevalence (5-10%) of CLL-associated AIC
followed by idiopathic thrombocytopenic purpura (ITP)
(2-5%), pure red cell aplasia (PRCA) (<1%), and
autoimmune neutropenia (AIN) (<1%).2,3 The prevalence
of AIN, however, may in fact be higher than reported
due to a lack of awareness of the condition and difficulty
in its diagnosis. 4 Despite its rarity, autoimmune
neutropenia can be a significant clinical challenge in
patients with CLL and can increase the risk of infectious
complications. Thus, the prompt diagnosis and
resolution of CLL-associated AIN is essential to the
management of these patients.
Ibrutinib is a selective inhibitor of Bruton tyrosine kinase
and induces a durable response in patients with CLL.5
The activity of ibrutinib in CLL-associated AIC is largely
unknown as pivotal clinical trials excluded patients with
AIC. We report a case of a patient with CLL who
experienced worsening of AIN after discontinuing
ibrutinib therapy. Given its immune modulatory effects,
these findings suggest ibrutinib may have a role in
controlling AIN in patients with CLL.

CASE PRESENTATION
This is a 72 year-old female who was diagnosed with
CLL in early 2000 after presenting with progressive left
cervical lymphadenopathy. Prognostic markers of CLL
were not evaluated at the time of diagnosis. She was
treated with fludarabine and rituximab and achieved a
complete response. She continued on active surveillance
for five years until she had evidence of disease
recurrence.
She was treated with single agent rituximab in 2005 and
then rituximab-bendamustine in 2009 and achieved
complete remission. In 2012, she had evidence of
disease progression with diffuse adenopathy and a
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biopsy was performed to rule out disease transformation.
FISH studies at that time revealed trisomy 12 and 17p
deletion. The patient did not wish to undergo further
chemotherapy and instead was treated with high dose
methylprednisolone with rituximab followed by
lenalidomide. Her CLL was controlled on this regimen,
however, she developed thrombocytopenia (platelet
count of 46,000 per cubic millimeter), leg heaviness,
and fatigue from the lenalidomide and it was stopped in
June 2014. Three weeks after stopping lenalidomide,
she developed incidental neutropenia with an absolute
neutrophil count (ANC) of 900 cells/µL. Due to a lack of
constitutional symptoms, she was not treated for her
neutropenia and her counts improved spontaneously.
In September 2014, she was started on ibrutinib for
disease progression and achieved a partial response.
However, by August 2017 she noted increased pelvic
lymphadenopathy and leukocytosis consistent with
progressive disease. Genome sequencing studies
revealed the presence of a BTKI mutation (C481S)
conferring resistance to ibrutinib as well as an IGH-BCL2
rearrangement, ATM R248, and NOTCH1. Ibrutinib was
discontinued in November 2017 and venetoclax was
initiated. Subsequently, her ANC began declining which
was initially thought to be a related side effect of
venetoclax (Figure 1). However, despite multiple dose
reductions and interrupting venetoclax for 7 weeks, her
ANC remained below 500 cells/uL. The differential
diagnosis at this time included myelodysplastic
syndrome and autoimmune neutropenia. Therefore, a
bone marrow biopsy was performed which revealed
only 10% involvement with CLL and no evidence of
myelodysplasia. Moreover, there was evidence of
myeloid maturation arrest fur ther suggesting
autoimmunity as her etiology of neutropenia. She
received oral steroids and rituximab which resulted in a
rapid resolution of her neutropenia. However, due to a
decreasing ANC (Figure 1), tbo-filgastrim was added to
her regimen every 10 days. Venetoclax was restarted, in
conjunction with tbo-filgastrim, and her ANC continued
to be maintained above 1000 cells/uL. She has remained
stable on this therapeutic regimen for almost one year.

Figure 1.

DISCUSSION
We present a case of worsening AIN after stopping
ibrutinib that was successfully managed with steroids,
rituximab, and infrequent growth factor support. AIN is
relatively uncommon in patients with CLL, but its
presence should be suspected if other causes of
neutropenia are ruled out. The pathogenesis of AICs in
patients with CLL is not well understood and is possibly
related to immune dysregulation including ineffective
regulatory T-cell function. Additionally, humoral
immunity can also be impacted as CLL cells may process
cryptic antigens differently from normal B cells and thus
present a peptide for which there is no immunological
tolerance.6 Lastly, AICs in patients with CLL can also be
drug-induced (purine analogs and alkylating agents).7
The role of ibrutinib in AIN is controversial and patients
with AICs were largely excluded from pivotal ibrutinib
clinical trials. In a retrospective analysis of 301 CLL
patients treated with ibrutinib at Ohio State University
Cancer Center, six patients developed treatmentemergent AICs. However, these episodes of AIC occurred
within 6 days to 23 months after ibrutinib initiation and
thus did not appear to be temporally linked to the
therapy. Furthermore, 25% of these patients had a past
history of AICs and 7% were already receiving active
therapy for AIC at the time of ibrutinib initiation.8
In the phase 3 RESONATE-1 study, which compared
ibrutinib vs. ofatumumab in previously treated CLL/SLL
patients, ibrutinib did not precipitate recurrent AICs in
patients with CLL who had a history of autoimmune
complications.9 In fact, ibrutinib may play a therapeutic
role in the prevention and treatment of AICs in patients
with CLL.10 This was illustrated in one retrospective study

using pooled data from four clinical trials which found
that AIC therapy was discontinued in 86% of patients
after a median of 4.7 months of initiating ibrutinib. 8
Similarly, our group previously reported a case of CLL
induced ITP that was successfully controlled with
ibrutinib and rapidly flared after brief ibrutinib discontinuation. 11 This also mirrors another case reported by
Molica et al where a patient with CLL-associated AIHA
experienced exacerbation of hemolysis twice after
stopping ibrutinib.12 Conversely, some reports suggest
that ibrutinib may initially and transiently worsen AIHA in
patients with CLL, but with continued use, it may
ultimately control AICs.
Our report suggests a role for ibrutinib in controlling
CLL-associated AICs including AIN. Ibrutinib has a variety
of mechanisms which can influence the immune system
and potentially influence AICs. It inhibits interleukin-2inducible kinase (ITK), which decreases the response of
autoreactive T cells and can also modulate cytokine levels
to promote a shift from a Th-2 towards a Th-1 mediated
immune response. Additionally, ibrutinib inhibits B-cell
receptor signaling which can inhibit the ability of B cells to
respond to produce pathologic antibodies.8 Literature on
this notion is currently conflicting and further research is
needed to better elucidate the relationship between
ibrutinib, CLL, and AICs.
CLL-associated AICs, such as AIN, are common
throughout the course of disease. Steroids, immunosuppressive, or granulocyte stimulating therapy in the case
of AIN are the current standard treatment options.
Ibrutinib may be a new therapeutic option for AIN
patients with concomitant treatment indications for their
underlying CLL. This case also illustrates that some
patients may develop an AIN flare after stopping ibrutinib.
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HEMATOLOGY & ONCOLOGY

Hyperviscosity in Non-IgM Lymphoplasmacytic
Lymphoma
Mario Fonseca-Paricio, MD, Sushil Ghimire, MD, and Adam Binder, MD

CASE
The following is a case of how a non-IgM paraproteinemia can present with symptoms of hyperviscosity
and coagulopathy, an uncommon occurrence.1-3 As this
case demonstrates, this diagnosis must be considered
even in patients with relatively normal coagulation
laboratory results. Such pathology requires urgent
treatment with plasmapheresis.
SS is a 64-year-old man who presented to the hospital
with a chief complaint of fatigue, rash, and leg swelling.
He reported feeling significantly more fatigued over the
last six months. The fatigue was present throughout the
day and marginally improved with rest. He denied any
chest pain or dyspnea. He followed with a primary care
physician for this fatigue. The workup overall was
non-diagnostic. Four weeks prior to presentation to the
hospital he developed intermittent night sweats,
subjective fevers, and chills. Moreover, for the last month
he had noticed swelling in his legs to the level of his
knees. Another concerning symptom for SS was a
worsening pruritic rash that he first noticed on his lower
extremities during the months prior. Initially, the rash was
localized, but became more diffuse over the past month.
The patient had no allergies. His only prior medical
condition was hypertension for which he was treated
with atenolol. There was no family history of malignancy
and the patient reported no past or current smoking,
alcohol use, or drug use. On review of systems he
reported having intermittent black spots on the periphery
of his visual fields as well as spontaneous gingival
bleeding.
Physical exam revealed diffuse, non-tender, firm
lymphadenopathy over the axilla and inguinal regions as
well as bilateral lower extremity edema. Skin exam
showed diffuse macular erythematous rash with annular
formation of palpable purpura over the posterior,
superior pelvis, as well as the upper and lower extremities.
Laboratory data was notable for hemoglobin of 8.6 g/dL
with a mean corpuscular volume of 102 fL, an elevated
protein gap with total protein of 11.2 g/dL and albumin
of 3.4 g/dL, as well as an elevated LDH at 790 U/L.
His serum immunoglobulin quantification showed
significantly elevated IgG at 5180 mg/dL (723-1,685 mg/
dL) with normal IgA and IgM at 75 mg/dL (69 - 382 mg/

dL) and 140 mg/dL (40 - 230 mg/dL) respectively. Serum
protein electrophoresis showed a monoclonal protein
band in the gamma region at 5.9 g/dL (0.5 – 1.6 g/dL),
which was further classified as IgG kappa. Kappa/
lambda ratio was calculated at 3.7. His blood repeatedly
clotted in the tube despite multiple attempts. Some
tests were unable to be performed due to increased
serum viscosity. He had inconsistent sodium levels
ranging between 113-150 mEq/L without intervention.
Hepatic function tests were normal, hepatitis B and C
were negative, and cryoglobulin testing was negative.
Peripheral flow cytometry showed no abnormal
population of B or T cells.
CT of the chest, abdomen, and pelvis showed bilateral
axillary, subpectoral, mediastinal, upper abdominal, and
retroperitoneal lymphadenopathy with no hepatomegaly
or ascites. Skin biopsy of the right thigh showed granular
deposition of IgM and C3 in the superficial vessels of the
skin consistent with leukocytoclastic vasculitis. Excisional
biopsy of the left axillary lymph node showed a small
B-cell lymphoma with plasmacytic differentiation. Flow
cytometry demonstrated a CD20 +, CD5 -, CD10 -,
monoclonal population. CD138 staining showed a
separate abundant plasma cell population and kappa
light chain restriction. Ki 67 was 10 percent. Bone
marrow biopsy showed no evidence of disease. These
findings are consistent with lymphoplasmacytic
lymphoma (LPL).
His hospital course was complicated by new hematuria
during his admission. PT time was slightly prolonged at
14.6 sec with a normal PTT; there were normal levels of
coagulation factors II, VII, X, XIII and fibrinogen. Despite
not having any laboratory data to confirm hyperviscosity,
the intermittent gingival bleeding, blurred vision, and
hematuria in the setting of IgG paraproteinemia was
consistent with hyperviscosity syndrome; for this, our
patient received urgent treatment.
The patient was placed on dexamethasone 40 mg daily
for 4 days and received 2 sessions of therapeutic plasma
exchange (TPE). After the TPE, his IgG protein decreased
to 1,899 mg/dL with clinical improvement. He was
deemed to be medically ready for discharge for
outpatient treatment with rituximab and bendamustine
for his non-IgM LPL presenting with hyperviscosity
syndrome.
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DISCUSSION

CONCLUSION

What makes this case rare is not only the diagnosis of a
non-IgM LPL, but also the clinical presentation of
hyperviscosity syndrome at IgG levels that usually do not
result in hyperviscosity. LPL is an indolent disease of
mature B cells with plasmacytic differentiation which
usually involves bone marrow and less frequently lymph
nodes and spleen.1 It is responsible for approximately 1%
of all hematological malignancies in the United States.2
Among LPLs, the most common form of LPL is IgM LPL,
accounting for approximately 95% of cases: with
non-IgM LPL accounting for approximately 5% of cases.

LPL has an indolent presentation due to proliferative
small B cells with plasma cells or plasmatoid lymphocytes.
It is important to stress that in a patient such as ours
presenting with signs of a coagulopathy such as visual
changes, gingival bleeding, and hematuria in the setting
of relatively normal coagulopathy labs to consider
hyperviscosity syndrome. It should also be considered in
the presence of elevated total protein and widened
protein gap. The hyperviscosity could be due to a
gammopathy such as the case presented as well as
multiple myeloma, acute leukemia, or polycythemias. In
the case of hyperviscosity secondary to a gammopathy,
the treatment of choice is TPE.

The presence of LPL with a monoclonal IgM, the most
common subtype, confers the diagnosis of
Waldenstrom’s macroglobulinemia.3 Hyperviscosity is a
well-recognized clinical syndrome of Waldenstrom’s
macroglobulinemia due to increase production of the
pentameter immunoglobulin IgM, the largest immunoglobulin with a molecular weight of 990 kDa.4 As a result,
hyperviscosity can occur at IgM levels as low as 3,000
mg/dL. This patient’s hyperviscosity, instead, presented
with an elevated IgG, a smaller immunoglobulin with
molecular weight 150 kDa. It is thereby less commonly
associated with symptoms of hyperviscosity and not
typically until levels are significantly elevated.5
The levels at which an IgG paraproteinemia would
present with hyperviscosity are inconsistent across
studies.6,7 There is some data that suggests that the risk
of hyperviscosity can vary with IgG subclass. For
example, IgG3 subclass can produce hyperviscosity at
lower levels compared to IgG1, partially explained by the
ability of certain subclasses to form concentration
dependent aggregates. 8,9 This phenomenon was
described in a case report in which the low molecular
weight IgG molecules aggregated to form trimers and
tetramers resulting in larger molecules and clinical
hyperviscosity syndrome.10
Regardless of the threshold and quantity of immunoglobulins, the American Society for Apheresis defines
hyperviscosity syndrome as a category I indication for
TPE.11 Our patient received 2 sessions of TPE as well as
4 doses of dexamethasone which overlapped with TPE
and showed good response to treatment.
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INFECTIOUS DISEASE

Subacute Onset Hand Clumsiness in a Renal
Transplant Patient with a Recent ICU Stay
William Bradford, MD

INTRODUCTION

OUTCOME AND FOLLOW UP

Solid organ transplant recipients carry a high burden of
disease and are susceptible to opportunistic infections
not seen in other patient subgroups. Signs and symptoms
that would not necessarily warrant timely attention in
other patient groups may call for an aggressive workup
in this subset of patients. Here, we present one case in
which a seemingly trivial complaint denoted serious
underlying pathology, and timely attention to this minor
but unusual concern led to early intervention with
appropriate treatment of an uncommon disorder.

Follow-up MRI brain confirmed the diagnosis of multiple
brain abscesses as well as a left parotid abscess.
Otolaryngology and interventional radiology were
consulted for parotid abscess aspiration. Gram stain of
this fluid demonstrated modified acid-fast branching
gram-positive rods. Following the CT head, the patient
was loaded with prophylactic antiepileptic drugs. Once
the organism was identified, the patient was started on
intravenous imipenem and sulfamethoxazoletrimethoprim (SMX-TMP). She was admitted to the
neurological intensive care unit for close monitoring of
her neurological status and monitoring for seizure activity.
The area of calf swelling was later determined to be an
abscess that was drained and revealed gram stain findings
similar to the parotid abscess. Cultures from both areas
as well as the blood eventually grew Nocardia farcinica/
Nocardia kroppenstedtii. She underwent TEE 3 days after
admission which was negative for any vegetation. Her
hospital course was lengthy and complicated by refractory
multifactorial thrombocytopenia, acute DVT, and acute
hypoxic respiratory failure due to flash pulmonary edema.

CASE DESCRIPTION
The patient is a 47-year-old female with a history of renal
transplant due to lupus glomerulonephropathy on
tacrolimus, prednisone, hydroxychloroquine, and
mycophenolate for immunosuppression and recurrent
otitis media who presented to the emergency
department for evaluation of ear pain consistent with
her prior episodes of otitis media. Her past medical
history was otherwise notable for a recent intubation for
flash pulmonary edema following hypertensive
emergency at an outside hospital. Review of systems
was notable for progressive bilateral hand clumsiness
over the past few days as well as an area of painful
swelling in the right calf. Her neurological examination
was remarkable for weakness of the bilateral hand
intrinsic muscles, diminished left hand proprioception,
and agraphia, but was otherwise normal. She underwent
computed tomography of the head without contrast,
which revealed multiple areas of vasogenic edema in
the white matter as well as a left parotid abscess.

DIFFERENTIAL DIAGNOSIS
The findings of agraphia and diminished proprioception
on neurological examination localized the lesion to the
brain—with agraphia, her most specific finding, most
associated with lesions in the language-dominant
superior parietal lobe.1 The differential diagnosis for CNS
pathologies in the immunocompromised host, while
very broad, should focus principally on infectious,
vascular, and neoplastic causes. Specific considerations
for this patient included intracranial hemorrhage,
posterior reversible leukoencephalopathy (given recent
hypertensive emergency), brain abscess, primary or
secondary CNS neoplasm, and CNS vasculitis.

DISCUSSION
A new focal neurological deficit in any patient should
prompt an expedient and aggressive workup. Evaluation
for stroke should be considered soon after such a deficit
is identified with prompt consideration for thrombolytic
therapy if appropriate. In the case of this patient, her
hand numbness and clumsiness represented a minor
incidental complaint for the patient, but the emergency
providers rightly maintained a high index of suspicion for
serious underlying pathology in the setting of a new
neurological deficit and opted for early head imaging. A
low threshold for head imaging is appropriate in the
transplant population, and likely prevented a serious
adverse outcome in this case.
Nocardiosis is an uncommon gram-positive bacterial
infection caused by aerobic bacteria in the genus
Nocardia. Disseminated nocardiosis (DN) typically
occurs in immunocompromised patients (approximately
2/3 of cases), but it can also occur in immunocompetent patients. DN can affect virtually any organ system
and is typically highly treatment-resistant, requiring
prolonged courses of intravenous antibiotics and
multiple source control procedures.2
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The risk of nocardiosis is highest in the first year following
solid organ transplant. Heart and lung transplant
recipients are at the highest risk, while liver and kidney
transplant recipients are at lower risk. Of note, most
transplant recipients with Nocardia infection were
actually on SMX-TMP prophylaxis prior to infection,
suggesting that SMX-TMP is not protective against
infection. Patients with recent exposure to high-dose
glucocorticoids, recent CMV infection, and elevated
calcineurin inhibitor levels were at relatively higher risk
of infection than matched controls.3,4
While this patient had disseminated disease and was
symptomatic from her CNS infection, her case
represents a relatively uncommon presentation. A
majority (77%) of transplant patients in one large study
had only pulmonary disease, whereas only 20% suffered
from disseminated disease.3

KEY POINTS
• A high clinical index of suspicion should be
maintained for opportunistic infection in all solid
organ transplant recipients, even when their
symptomatology is not suggestive of infection.
• Nocardiosis is a difficult to treat infection that can
be associated with a wide spectrum of disease but
occurs most commonly in the pulmonary form. It is
predominantly seen in immunosuppressed
populations.
• Disseminated nocardiosis often requires prolonged
courses of intravenous antibiotics and multiple
source control procedures for adequate treatment.
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PULMONARY MEDICINE

Hemothorax and Hemorrhagic Ascites:
A Rare Presentation of Endometriosis
Harry Wang, MD

INTRODUCTION
Endometriosis is a common diagnosis in reproductive
age women characterized by the presence of endometrial
tissue outside the uterine cavity.1 Although it is typically
confined to the pelvis, rare manifestations involving the
thorax, abdomen or pericardium have been documented.2-5
Even more rare is the concurrent presence of endometriosis-associated hemorrhagic pleural effusion and
ascites, which can prove a diagnostic challenge. We
describe a case of hemothorax and hemorrhagic ascites
in a woman with shortness of breath and abdominal pain.

panel and complete blood count were otherwise within
normal limits. Chest and abdominal computed tomography
(CT) imaging revealed a large loculated right-sided pleural
effusion, large-volume ascites (Figure 1) without cirrhosis
and a 5 cm multicystic right adnexal mass (Figure 2).
Thoracentesis and paracentesis were performed, both
yielding grossly bloody fluid. Cultures and gram and
acid-fast stains of both fluid samples revealed no
organisms, and cytology was negative for malignancy;
HIV and hepatitis serologies were negative and the
serum-ascites albumin gradient was less than 1.0. A
right-sided chest tube was placed to facilitate further
drainage (Figure 3); this was subsequently removed after
several days of minimal drainage. A transvaginal pelvic
ultrasound revealed a cystic right ovarian mass with
thickened, nodular internal septations. CA 125 was mildly
elevated, but CEA and CA 19-9 were normal.

Figure 1. CT imaging showing moderate simple ascites throughout the
abdomen.

CASE PRESENTATION
A 41-year-old woman with a history of bilateral spontaneous
pneumothoraces (4-5 years ago), congenital hearing loss,
anemia, and peptic ulcer disease presented to the ED with
several days of pleuritic chest pain, dyspnea on exertion,
and abdominal pain. She denied fevers, chills, night sweats,
cough, hemoptysis, vaginal bleeding, or pelvic pain, but
did endorse a 14-pound unintentional weight loss over the
past several months with no change in appetite. Her last
menstrual period was exactly 1 month prior to presentation.
On exam, patient had a temperature of 99.6F, blood
pressure of 92/54 mmHg, heart rate of 83 bpm, and
oxygen saturation of 99% on room air. She was
thin-appearing with a distended abdomen that was
diffusely tender to palpation. There were decreased breath
sounds in her right lower lung field, but she was clear to
auscultation on the left side. Initial laboratory studies were
only notable for microcytic anemia (hemoglobin 12.3 g/
dL) and elevated CRP (18.4 mg/dL). Her basic metabolic

Figure 2. CT imaging demonstrating a multicystic 5.1 cm right adnexal mass.

Figure 3. CT imaging showing a right mediastinal loculated fluid collection
with a right-sided chest tube in place (arrow).
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DIFFERENTIAL DIAGNOSIS
Mr. M suffered discrete episodes of altered mental status
that were precipitated by anesthesia, sleep deprivation
due to late lab draws, nighttime administration of
ciprofloxacin and baclofen, and known triggers of his
post-traumatic stress disorder (including hospital
helicopter landings and thirst). These episodes decreased
in frequency with adequate sleep, reorientation measures,
control of his thirst, use of atypical antipsychotics, and
removal of a fecal management system. His ammonia
was elevated initially at 49, at which point he was
empirically started on lactulose and rifaximin with stool
output at or above goal. He was euglycemic throughout
his stay. The patient had no kidney disease or elevated
BUN to suggest uremia. Exhaustive brain imaging did not
re v e a l a n y s i g n i f i c a n t i n t r a c r a n i a l p a t h o l o g y.
Comprehensive infectious workup found no new infection
or recurrence of his previous joint infection. Given his
critical illness, waxing and waning mental status, and lack
of improvement despite correction of other identifiable
causes, the diagnosis of delirium was made.

DIFFERENTIAL DIAGNOSIS
The differential for bloody pleural effusion and ascites
includes a variety of infectious and inflammatory
etiologies. Her history of bilateral spontaneous pneumothoraces and congenital hearing loss could suggest an
autoimmune or connective tissue disorder; anti-nuclear
antibody, rheumatoid factor, anti-glomerular basement
membrane antibody, and anti-neutrophil cytoplasmic
antibody were negative. She was appropriately worked up
for HIV, viral hepatitis and tuberculosis, and cultures were
unrevealing. She had no signs of cirrhosis or portal
hypertension on imaging. A prominent finding on
abdominal imaging was the ovarian mass, as that could
point toward malignancy or ruptured hemorrhagic
ovarian cyst. In the setting of both pleural effusion and
ascites, the presence of an ovarian tumor completes the
triad of findings for Meigs syndrome, a relatively benign
condition in which both fluid collections resolve after
resection of the tumor.

OUTCOME AND FOLLOW UP
Given the concern for malignancy or Meigs syndrome,
patient underwent diagnostic laparoscopy in which
850cc of bloody ascites was evacuated; during this
procedure, extensive endometriosis was noted on the
peritoneal surfaces with bilateral hydrosalpinx. No active
source of bleeding was identified. Both ovaries were
devoid of endometriotic implants, so the planned adnexal
mass resection was aborted. Post-operatively, her
dyspnea and abdominal pain improved, and she was able
to be discharged in two days with gynecology follow-up.
The patient presented for clinical follow-up with her
gynecologist 2 weeks after discharge. She reported
minimal pain, normal bowel and bladder function and
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could tolerate a regular diet. Pathology from the
evacuation revealed no malignancy, and medical and
surgical (adnexal resection) options were discussed. The
patient opted for observation only, as she desired to have
another child in the future.

DISCUSSION
This case illustrates the importance of suspecting atypical
presentations of endometriosis. The simultaneous
presence of hemothorax and hemoperitoneum suggests
a communication via diaphragmatic pores, a similar
mechanism to that of hepatic hydrothorax.2 Given this
patient’s presentation and imaging findings, infection and
malignancy were aggressively and appropriately worked
up, but it is crucial for internists not to omit this relatively
common diagnosis from the differential, especially since
the management is typically uncomplicated. Meigs
syndrome was also an important consideration, as it is
characterized by the triad of benign ovarian tumor, pleural
effusion and ascites; fluid collections typically resolve
after tumor resection in Meigs syndrome.6 Treatment
options for endometriosis range from simple observation
to medical therapy with leuprolide or nonsteroidal
anti-inflammatories. For patients with bloody pleural
effusions and ascites refractory to medical management,
more definitive therapy may involve hysterectomy with
salpingo-oophorectomy.1

KEY POINTS
• Hemorrhagic ascites and hemothorax are uncommon
presentations of endometriosis that require extensive
initial evaluation for infection and malignancy.
• Meigs syndrome should be considered in young
women presenting with the triad of benign ovarian
tumor, pleural effusion and ascites
• Treatment for endometriosis can var y from
observation, NSAID therapy to surgical evacuation
and hysterectomy with salpingo-oophorectomy.
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RHEUMATOLOGY

Pneumatosis Intestinalis in a Patient with
Systemic Lupus Erythematosus
Sean Dikdan, MD and Michael Lake, MD

INTRODUCTION
Pneumatosis intestinalis (PI) refers to the radiographic
finding of gas within the small or large bowel wall. It
can be seen in association with gas in the portal venous
system. The clinical significance of these findings is
variable and depends on the patient's etiology and
initial presentation. PI can be seen anywhere in the
gastrointestinal tract distal to the stomach and is caused
by a myriad of conditions.1 We present a case of a
patient admitted to the intensive care unit with PI and
portal vein gas.

CASE DESCRIPTION
A 46 year-old woman with a past medical history of
lupus and recent stroke presented to the emergency
department (ED) with chief complaint of syncope. She
was boarding a flight when she became suddenly
unresponsive. She was awoken by her family and taken
to the nearest ED. On arrival, she reported intermittent
hematochezia and diffuse abdominal pain for a week
prior to the presentation. Her past medical history was
pertinent for a stroke two weeks prior to presentation
for which she was started on anti-platelet agents (aspirin
and clopidogrel). She was taking prednisone and had
started belimumab therapy for her lupus, with the most
recent treatment one month earlier.
She was afebrile with an initial blood pressure of 65/30
mm Hg, heart rate of 74 beats per minute, and
respiratory rate of 30 breaths per minute. On exam, she
was distressed and had mottled skin on her extremities.
She was alert and oriented to person, place, and time.
Cardiac and pulmonary exam was normal. Her
abdomen was soft and distended with mild, diffuse
tenderness to soft palpation. Guaiac stool testing was
positive. Admission laboratory values revealed a
hemoglobin of 6.4 g/dL, white blood cell count of
28,200 per cubic millimeter, lactate of 15.0 mmol/L,
and an arterial blood pH of 7.07. Other inflammatory
markers were not checked. She was given three liters
of intravenous fluid in the ED and had an emergent
computed tomography (CT) scan of the abdomen and
pelvis. These scans showed air within the colonic wall
and the portal venous system (Figures 1 and 2).

Figure 1. Coronal image of non-contrast CT scan showing air within the
colonic wall.

Figure 2. Axial image of non-contrast CT scan showing air within the
portal venous system.
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DIFFERENTIAL DIAGNOSIS
Imaging allowed the medical team to focus the
differential diagnosis on likely causes of PI in this patient.
Stool, mucosal lesions, or submucosal lesions may be
mistaken for PI, so making the diagnosis should involve
clinical correlation and consultation with a radiologist.2
Once the diagnosis is confirmed, an etiology should be
determined. This finding has a broad differential, which
i n c l u d e d i s c h e m i c , i nfe c t i o u s , i nf l a m m at o r y,
immunologic, endocrine, and iatrogenic causes. Lupus
is occasionally associated with mesenteric ischemia or
ischemic colitis, a known cause of pneumatosis
intestinalis. Infectious colitis and intra-abdominal sepsis
may present similarly and have explained her hypotension
and acidosis. Inflammatory conditions of the bowel
such as celiac disease have been associated with the
finding as well. 3 The use of immunosuppressive
monoclonal antibody therapy may have contributed to
the development of her PI and affected healing of the
bowel wall. 4 Cases have been described with
bevacizumab and sunitinib. This patient was on
belimumab, which inhibits B-cell activating factor.
Iatrogenic PI can be seen after bowel surgery or
endoscopy and typically has a benign course; this did
not seem likely in this patient.

OUTCOME
Treatment with fluid resuscitation, vasopressors, packed
red cell transfusion, and broad-spectrum antibiotics was
continued on admission to the intensive care unit.
General surgery was consulted for urgent laparotomy,
but it was felt that the patient was too unstable and
would not survive the surgery. She remained hypotensive
despite maximum dosages of four vasopressors. She
developed worsening encephalopathy and urine output
ceased. Five hours after presentation, the patient had a
cardiac arrest and died after receiving advanced cardiovascular life support.

DISCUSSION
PI can be found incidentally or in patients who have
intra-abdominal catastrophe. This case demonstrates
the rapid clinical decline that can be associated with
this finding. The portal vein gas shown in Figure 2 is
subtle and can be mistaken for air in the biliary tree. It
is seen when there is significant bowel ischemia and
portends an even worse prognosis. 5 In critically ill
patients, urgent surgical intervention is indicated as was
initially sought here. In non-critically ill patients, culprit
medications should be discontinued and antibiotics
given until resolution of PI. Data also supports the use
of an elemental diet.6
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Although this patient warranted surgical intervention,
her rapid deterioration prevented her from undergoing
surgery. This patient’s lupus was presumed to be severe,
as it had recently caused a stroke despite medical
therapy. A diagnosis of antiphospholipid antibody was
possible, but diagnostic studies were not sent. The
chronic colonic inflammation and vasculitis associated
with lupus had been contributing to the ongoing bloody
diarrhea and eventual ischemic colitis. The ongoing
abdominal insult eventually led to her shock and death.7,8

KEY POINTS
• Pneumatosis intestinalis seen on imaging is associated
with significant mortality and concomitant portal
venous gas worsens the prognosis.
• Syncope and gastrointestinal bleeding in a patient with
underlying autoimmune disease may represent intraabdominal catastrophe and merits expedited workup.
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ORIGINAL ARTICLE

Resident Experiences with Journaling
Tara Sunder, MD, Gretchen Diemer, MD, and Vikas Sunder, MD

BACKGROUND
Each year, medical school graduates don their long white
coat for the first time and begin their residency. While
residency promises the excitement of learning and
increased autonomy, it also brings long duty hours and
stressful situations worsened by inexperience. Due to
these stressors, burnout affects many residents each year.
Studies have been done to see if wellness curricula help
decrease resident burnout, and since journaling is a known
way to relieve stress and enhance reflection, journaling
has become a common intervention in these curricula.1,2
While there are studies evaluating the impact of journaling
on mental health and stress relief, the data is still limited
on journaling specifically in the resident population. The
aim of this educational intervention is to expose internal
medicine residents to journaling as a way to mitigate
burnout and survey their responses to the intervention.

METHODS
Forty-six incoming, first year Internal Medicine residents at
Thomas Jefferson University Hospital were given a journal
during their residency orientation. Each week for 10 weeks,
a writing prompt was sent via text message in one of four
categories: creative fiction, gratitude, patient care, and
personal reflection. Example prompts included: “What did
you learn from a patient this week? What did you teach a
patient this week? What is your goal for your next rotation?”
In addition to the prompt, there was also a link to a short
survey (Table 1) that assessed response rate, journaling
beyond the prompt, and current clinical rotation.
Additionally, burnout was measured via a two-question
burnout index in the survey based on the Maslach Burnout
Inventory.4 A three month follow up survey was distributed
via email to gather more responses to the journaling
process (Table 2). The journals were not collected, and
residents did not have to share the contents of the journal.

RESULTS
The overall response rate to the survey was 41%. Thirty-two
percent of responding residents journaled before residency
and 42% had used their journal since receiving it at
orientation. Residents who journaled reported they “enjoy
it” and called it “a good way to reflect.” The biggest barriers
to journaling were time and/or fatigue (59% of respondents).
Regarding burnout, prior to residency, 26% of responding
residents reported feeling burned out from work up to
once a month. In comparison, 68% of responding
residents reported they felt burned out from work up to
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once a month or more (includes survey response options
of once a month or less, a few times a month, once a
week, a few times a week, or daily).

DISCUSSION
Through this educational intervention, more residents
were exposed to journaling as a way to relieve stress.
Based on the open-ended survey question, those who
did write in their journals enjoyed the experience. The
data also showed that residents found the weekly
prompts, which attempted to promote reflection and
creative thinking, helpful even if they did not write in
their journal.
One limitation of the study was the lack of an in-person
meeting to discuss journaling as a means of relieving
stress. Reflective writing is a way to express thoughts
and emotions on paper. That being said, there does not
necessarily need to be a technical structure or
“correctness” to the writing. In fact, the writing may have
more impact if it reflects one’s own self-expression. This
should include all writing styles and perhaps even be
expanded to include drawings, poetry, song lyrics, or
graphic novels. Including many different writing styles
into the journal may be a way to expose residents to
journaling in a less traditional sense, but may reach more
residents who did not feel that traditional reflective
writing could be incorporated into their daily routine. A
way to overcome this limitation in the future would be
to incorporate this discussion into the orientation when
the residents first get their journals. As many of the
residents found the prompts helpful to reflect on,
opening the journal to include more forms of
self-expression may increase the number of residents
who write in their journal to put their reflection on paper.
Lack of time was the other significant barrier for residents
writing in their journal. Residency already diminishes
residents’ free time and puts a strain on the work-life
balance, often contributing to the burnout in the first
place. Therefore, adding an additional task for residents
is not the intention of this educational intervention.
Future directions would include more structured
journaling time during residency to increase exposure to
journaling. This could be done by incorporating
journaling into the already established “intern stress
relief” hour that takes place once a month during the
noon conference hour. This would expose more
residents to journaling as it would take place during a
structured hour.

Table 1

Table 2

Question

Answer choices

Question

Answer choices

Did you answer last week’s
journal prompt?

Yes; No

Open ended

Did you write in your journal
outside of the prompt?

Prior to residency did you ever
write in a journal? If so, what was
your experience?

Yes; No

What type of rotation are you on?

Floors; Outpatient; ICU; Elective

Since getting your journal at
orientation, how frequently have
you used your journal?

Never; Once every few months;
Once a Month; Once a week;
A few times a week; daily

I feel burned out from my work

Never; A few times a year or less;
Once a month or less; A few
times a month, Once a week;
A few times a week; Every day

If you used your journal,
what were your thoughts on
journaling?

Open ended

I have become more callous
toward people since I took
this job

Never, A few times a year or less,
Once a month or less, A few
times a month, Once a week,
A few times a week, Every day

If you did not use your journal,
what did you feel was the biggest
barrier to doing so?

Open ended

Did you find the weekly prompts
helpful?

Open ended

Is there a way other than text
message you would rather receive
the prompt?

Open ended

Did you journal outside of
responding to the prompt?

Open ended

Prior to residency, how often
did you feel burned out from
your work?

Never; A few times a year or less;
Once a month or less;
A few times a month; Once a week;
A few times a week; Daily

Currently, how often do you feel
burned out from your work?

Never, A few times a year or less;
Once a month or less;
A few times a month; Once a week;
A few times a week; Daily

The strength of this project is the positive response
residents who journaled provided regarding the
journaling process as a way to minimize burnout.
Additionally, this project shows the achievability of
getting a journal for each incoming resident and sending
a journaling prompt each week. Text message was used
to send the prompt as it is typically accessed more
readily than email. There was also faculty support. This
shows that an ongoing journaling curriculum could be
achieved to expose residents each year to journaling as
a means of decreasing burnout.

CONCLUSIONS
As burnout increased from 26% prior to residency to 68%
at three months into residency, the survey data reaffirms
that burnout is a significant issue among incoming
Internal Medicine residents. The qualitative responses to
the survey showed that residents who journaled found it
beneficial. However, more survey data is needed to study
the effect of journaling on resident burnout. The data also
reflected that lack of time was a main cause of not using
the journal. Therefore, a future direction of the project
would be incorporating journaling into the resident
wellness program.
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EDITORIAL

Can Our Hearts Take the New Guidelines?
Eitan Frankel, MD

After getting sign-out for the Heart Failure service, I
excitedly went to meet Mr. G. Two months ago, while
on a different service, I frequently watched him bustle
through the hospital hallways with his IV pole in hand.
He smiled, spoke cordially with nurses and staff, and
took time to greet house-staff not directly involved with
his care. Thus, you can imagine my surprise when I
entered his room and encountered a forlorn face with a
few days of stubble complaining about cold eggs and
toast. He hadn’t been on a walk in days.
Unfortunately, the scene I am describing is likely familiar
to anyone involved with inpatient, heart failure care. Mr.
G is a 67 year-old-male with ischemic cardiomyopathy
(left ventricular ejection fraction 10-15%) on outpatient
milrinone who was admitted for expedited heart
transplant evaluation in the setting of worsening
symptoms and hemodynamics. His milrinone was
increased to the maximum dose and a Swan Ganz
catheter was placed. In early September 2018, he was
listed as status 1A, the highest level prior to transplant.
For the next month, Mr. G cheerfully greeted the resident
at 7am, persuaded nurses to slip him extra chocolate,
and set new records on his daily walks.
Then overnight, on October 18th 2018, the new transplant
listing criteria went into effect and everything changed.
Allocation of organ transplantation in the United States
is managed by the United Network for Organ Sharing
(UNOS) and is dependent on an intricate system. Due to
the relative scarcity, there is no easy way to justly and
effectively allocate hearts. Over the past few years,
there had been a growing consensus that the old listing
system had significant problems: there were too many
status 1A patients, there was inadequate organ allocation
to certain high risk candidates, allocation rules were not
aligned with prognosis, and there were unintended
geographic disparities.1 Thus, in October, a new set of
guidelines went into effect that changed the criteria for
urgency status (Table 1) and increased the geographical
distance for organ procurement to 500 miles.2 According
to the new guidelines, only three categories of patients
are considered Status 1: those on VA ECMO (who can be
listed as Status 1 for 7 days), those who are
non-dischargeable with biventricular devices, and those
who have mechanical circulatory support devices and
life-threatening arrhythmias. 2 These changes to the
criteria for medical urgency in orthotopic heart
transplants were not unexpected, but there remain
unsolved system-wide and patient-centered questions
that the cardiology community needs to address.

34 | The Medicine Forum, Volume 20

5

One question is what will happen to the metric of
one-year survival after transplant? While one-year
survival has traditionally been the gold standard for
evaluating transplant programs, historical data suggests
that if programs elect to transplant the highest risk
patients (i.e. ECMO patients), outcomes will worsen.
Since the 1980s, the International Society for Heart and
Lung Transplantation (ISHLT) has compiled a registry of
141,268 heart transplants and published an annual report
with statistics and outcome data. 3 As mechanical
circulatory support (MCS) has become safer and more
efficacious, an increasing number of transplants are
being bridged by MCS (26.0% from 2004 to 2008 vs.
43.0% from 2009-2014). 3 While patients with left
ventricular assist devices, biventricular assist devices,
and no mechanical support (plus or minus inotropes) do
comparably well after transplant, extracorporeal
membrane oxygenation (ECMO) patients continue to
lag in their one-year survival rates (80-85% vs 60%,
p<.05).4 A separate retrospective cohort study looking at
post-heart transplant mortality among 157
ECMO-supported adults between 2000 and 2015
demonstrated similar results. The overall one-year
survival rate was 57.8%, and it was significantly worse
among patients with renal insufficiency (defined as GFR
<45 ml/min/1.73 m2 or dialysis dependent), mechanical
ventilation, or both of these comorbidities (52.3% vs
55.3% vs 12.5%).4 It is important to note that there are
significant limitations to each of these studies; both
studies were retrospective and did not evaluate center
expertise. While it is possible transplant outcomes
among ECMO patients may improve with increasing
usage and familiarity, it is unlikely that 1-year survival will
reach the 90% one-year survival benchmark to which
programs are currently held accountable. Given this
existing historical data, current transplant programs will
have to make a difficult decision: whether to take
advantage of increased donor availability for Status 1A
patients and accept the risk of transplanting high-risk
patients, or whether to defer operating on these patients
in order to protect outcome statistics.
While the validity of one-year survival as a metric of
transplant program success is only one of many
system-wide issues related to the new guidelines, this
conversation would be incomplete without returning to
the case of Mr. G and focusing on the patient-centered
effects. Even though Mr. G did not miraculously improve
or titrate off inotropes, overnight his listing status
changed from 1A to 3. At a statistical level, the outcomes
of old Status 1A and new Status 3 can be compared.

Table 1: PFTs from September 2016
Criteria Requirements in Adult Heart Allocation Policy
Old Guidelines
Status

Criteria

New Guidelines
Status
1

1A

1B
2

7

"Transplant candidate must be admitted to listing
transplant center hospital and have at least one of the
following devices or therapies in place:
1) Mechanical circulatory support for acute hemodynamic
decompensation (LVAD <30 days,
TAH, IABP, ECMO)
2) MCS with device complications
3) Continuous mechanical ventilation
4) Continuous infusion of a single high-dose intravenous
inotrope or multiple intravenous inotropes, in addition to
continuous hemodynamic monitoring of left ventricular
filling pressures"

"Transplant candidate listed must have at least one of the
following devices or therapies in place:
1) Left and/or right ventricular assist device implanted
2) Continuous infusion of intravenous inotropes"

2

3

This data will take a few years to collect, but hopefully
our patients will do just as well as before. But much
more difficult to measure will be the emotional and
psychological effects of the shifting guidelines on
current transplant candidates.
Mr. G was devastated when he heard his status had been
downgraded to Status 3. After remaining upbeat and
hopeful for months, while feeling that he was slowly
approaching the end of the tunnel, he suddenly had no
idea if or when he might receive a transplant. The
unpaid bills at home and his familial responsibilities
started taking a toll on his mood, and the once hospital
marathoner grew increasingly despondent and
frustrated; he frequently discussed leaving the hospital
without a new heart. And while he understood that that
there were valid reasons behind the guideline changes,
he still felt betrayed by the system and the fact that he
wasn’t grandfathered in.

"1) VA ECMO
2) Non-dischargeable, surgically implanted, non-endovascular
biventricular support device
3) MCSD with life-threatening ventricular arrhythmias"
"1) Non-dischargeable, surgically implanted, non-endovascular LVAD
2) IABP
3) Vtach/Vfib
4) MCSD with device malfunction
5) TAH, BiVAD, RVAD, or VAD
6) Percutaneous endovascular MCSD "
"1) Dischargeable LVAD (<30 days)
2) Multiple inotropes or single high-dose inotrope with continuous
hemodynamic monitoring
3) VA ECMO after 7 days; percutaneous endovascular circulatory
support device or IABP after 14 days
4) Non-dischargeable, surgically implanted, non-endovascular LVAD
after 14 days
5) MCSD with device infection. hemolysis, pump thrombosis, right heart
failure, mucosal bleeding, aortic insufficiency"

4

"1) Dischargeable LVAD
2) Inotrope without hemodynamic monitoring
3) Re-transplant
4) Congenital heart disease, intractable angina, HCM, restrictive cardiomyopathy, amyloidosis"

5

On the waitlist for at least one other organ at the same hospital

6

All remaining active candidates

A transplant candidate who does not meet the criteria for
Status 1A or 1B
A transplant candidate who is considered temporarily
unsuitable to receive a heart transplant

Criteria

REFERENCES
1. Fudim M. The Future of the Adult Heart Allocation System in the United States
[Internet]. American College of Cardiology. 2017 [cited 2018 Dec 19];Available
from: https://www.acc.org/latest-in-cardiology/articles/2017/02/09/07/24/
the-future-of-the-adult-heart-allocation-system-in-the-us.
2. Adult Heart Allocation [Internet]. Organ Procurement and Transplantation
Network. 2018 [cited 2018 Dec 19]; Available from: https://optn.transplant.hrsa.
gov/learn/professional-education/adult-heart-allocation/.
3. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb
SB, Levvey BJ, Lund LH, Meiser B, Rossano JW, Stehlik J. The Registry of the
International Society for Heart and Lung Transplantation: Thirty-second Official
Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme:
Early Graft Failure. The Journal of Heart and Lung Transplantation. 2015;34:
1264–1277.
4. Zalawadiya S, Fudim M, Bhat G, Cotts W, Lindenfeld J. Extracorporeal membrane
oxygenation support and post-heart transplant outcomes among United States
adults. The Journal of Heart and Lung Transplantation. 2017;36: 77–81.

And I don’t blame him one bit.
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LITERATURE REVIEW

A Gram-Negative False-Negative: Normal
Procalcitonin Level in a Patient with Multiple
Klebsiella Pneumoniae Intra-Abdominal Abscesses:
A Case Report and Literature Review
Mario D. Caldararo, MD

INTRODUCTION
Despite over 3,000 peer-reviewed articles on
procalcitonin (PCT) since 2004, guidance on its usage
is sparse.1 An analysis of more than 500 United States
hospitals in the Premier Healthcare Database found
large differences in utilization exist across regions (115
PCT encounters per 10,000 patients in the Northeast vs.
408 to 576 in other regions) and teaching vs.
non-teaching hospitals (345 vs. 530 PCT encounters
per 10,000 patients, respectively).2 The purpose of this
work is to describe a case that exemplifies the caveats
in PCT interpretation and to summarize the current
knowledge of the clinical utilization of PCT.

CASE PRESENTATION
A 78-year-old male with a history of hypothyroidism,
Lewy body dementia and long-term central venous
access for nutritional infusions was admitted for the
radiologically-guided placement of drains into newly
found intra-abdominal abscesses seen at an outside
hospital. On presentation he was nonverbal. Family
reported the abscesses were found incidentally; the
patient had not displayed any different behaviors or
symptoms. He had begun receiving ertapenem for
seven days prior to admission. His home medications
included anastrazole, Westhroid TM (a pork thyroid
preparation), and supplemental nutrients including
bearberry leaf extract, CoQ-10, cholecalciferol, boron,
huperzine serrate, EndefenTM, L-carnitine, niacin, DHEA,
and taurine.
On admission, his vitals included temperature 96.2° F,
heart rate 80 beats per minute, blood pressure 121/55
mmHg, respiratory rate 18 breaths per minute, and
SpO2 of 97% on room air. Physical exam revealed a frail
and cachectic, but non-toxic appearing elderly man
with diffuse abdominal tenderness. Laboratory studies
were notable for white blood cell count 20.6 x 109/L
[4,000-11,000 x 109/L] with 87.0% neutrophils [40-80%]
on automated differential (manual differential not
performed for band forms), hemoglobin 9.2 g/dL
[13.5-16.5 g/dL], platelets 422 x 109/L [150-450 x 109/L],
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sodium 135 mmol/L [135-145 mmol/L], bicarbonate 24
mmol/L [22-32 mmol/L], normal anion gap, blood urea
nitrogen 11 mg/dL [7-20 mg/dL], creatinine 1.0 mg/dL
[0.6-1.2], normal liver enzymes and coagulation studies.
C-reactive protein was 5.50 mg/dL. Erythrocyte
sedimentation rate was 80 mm/hr. TSH was 43.15 µIU/
mL with a low T4 of 0.4 ng/dL. Procalcitonin was 0.07
ng/mL (upper limit of normal 0.09 ng/mL).
CT of the abdomen and pelvis showed four fluid
collections concerning for abscesses: a left lateral
abdominal wall collection measuring 13.7 x 11.6 x 3.0
cm that contained multiple foci of air, a left lower
quadrant collection measuring 8.1 x 3.6 x 2.8 cm, a
prevesical collection measuring 7.4 x 6.8 x 1.3 cm, and
a right lower quadrant collection anteriorly measuring
7.8 x 0.9 x 0.6 cm. On hospital day two, interventional
radiology placed drainage catheters into the left lateral
and left lower quadrant collections. Cultures grew
moderate to heavy growth multi-drug resistant
Klebsiella pneumoniae (Figure 1).
The patient remained stable and white blood cell count
trended down. He continued to receive ertapenem. He
was discharged on day three with plans to follow-up
with interventional radiology for drain removal.

Figure 1. Antibiotic sensitivities for the Klebsiella pneumonia isolate
aspirated from the patient’s intra-abdominal abscesses.

REVIEW OF LITERATURE
Under normal physiologic conditions, PCT is a
prohormone produced in the thyroid gland that is further
processed to yield calcitonin, one of the primary
hormones involved in calcium homeostasis. During
bacterial infections, other tissues begin expressing PCT
without processing it into calcitonin, or having detectable
effects on calcium homeostasis.3,4 While this finding has
raised considerable in the usage of PCT as a specific
marker of bacterial infections, the biological function of
extra-thyroidal PCT remains unknown.5
The Food and Drug Administration (FDA) has approved
the use of PCT assays as a guide for beginning and
discontinuing antibiotic therapy in suspected lower
respiratory tract infections.1 The FDA indication was
informed in part by a Cochrane review that found
PCT-guided antibiotic therapy in acute respiratory tract
infections reduced antibiotic usage and mortality risk.6
The FDA also approved using PCT to guide de-escalation
of antibiotics during sepsis.
Although PCT-guided antibiotic prescribing algorithms
are intended to decrease the use and duration of
antibiotics, data are mixed. Huang et al note two main
criticisms of existing clinical trials: that they were
conducted in Europe where antibiotic prescribing
practices may differ from the United States, and that
physicians could override the PCT-guided algorithms.7 To
address these criticisms, their group conducted a large
trial in the United States: finding that PCT-guided
algorithms did not change the number of antibiotic-days
patients received.7
There are only a few Infectious Disease Society of
America (IDSA) guidelines in which PCT appears. A 2016
IDSA guideline on antibiotic stewardship contains a weak
recommendation for serial PCT measurements for
guidance of antibiotic de-escalation in adult ICU patients.8
A 2017 IDSA guideline contains weak recommendations
for using serum PCT to differentiate between
cerebrospinal fluid abnormalities due to surgery or
intracranial hemorrhage vs. bacterial infection. The weak
recommendation also extends to healthcare-associated
bacterial ventriculitis and meningitis, which are based on
studies reporting serum PCT having 100% specificity for
bacterial meningitis.9-11 A separate 2016 IDSA guideline on
hospital-acquired pneumonia recommends against the
usage of PCT to initiate antibiotics. 12 IDSA 2007
community-acquired pneumonia guidelines do not
make recommendations for or against usage of PCT.
Data for the utility of PCT as it pertains to localized
infections and abscesses are limited. A review on PCT in
localized infections by Saeed, Ahmad, and Dryden
reported two small (<100 patients) studies showing
promise for using PCT to determine the need for
antibiotics in wound infection.13 The studies, however,

suffered major limitations including heterogeneous
samples in one and a lack of control group in the other.
PCT for diagnostic aide in diabetic foot infection had
mixed data with positive results appearing with low
thresholds (0.2-0.5 ng/mL). Data do not support usage of
PCT in diagnosis of septic arthritis and was not found to
be a reliable marker over several small studies in
osteomyelitis without sepsis.
Soderquist et al found patients with non-bacteremic
septic arthritis and crystal-induced arthritides had similar
PCT levels.14 Hammer et al found lower PCT levels in
localized infections when trying to discern between
infection and acute rejection in transplant recipients;
however, abscesses were not specified as one of the
localized infections studied.15 Gendrel et al found lower,
but still elevated, PCT levels in pediatric patients with
localized vs. generalized infections.16 In contrast, an
abstract published in 2013 reported PCT to be a specific
marker for intra-abdominal abscesses in Crohn’s disease
with a higher mean serum PCT compared to patients
without abscesses, however, ranges were not specified.17
Another study conducted in 10 patients on extracorporeal oxygen therapy—with one of them having an
abscess—concluded PCT performed well as an indicator
of infection.18

CASE DISCUSSION
The focus of this report is the normal-range PCT level in
the context of confirmed intra-abdominal bacterial
infection with evidence of a systemic response
(leukocytosis, hypothermia, elevated inflammatory
markers) and organ damage (acute kidney injury).
The case raises the question of the effect of hypothyroidism on PCT measurements, which is not well studied.
One study involving 24 patients who had received total
thyroidectomy for medullary thyroid carcinoma showed
that PCT was not decreased; however, fourteen patients
were found to have residual thyroid tissue on ultrasound,
eight had regional recurrence, and two had distant
metastases.19 In a study involving patients with Hashimoto’s
thyroiditis, those with Hashimoto’s had higher mean PCT
levels than controls, and PCT was positively correlated
with anti-thyroglobulin and anti-thyroid peroxidase
levels.20 Based on these data, there is either a paradoxical
effect on PCT levels or no effect at all, which is in
accordance with the understanding that PCT in infected
states is extra-thyroidal in nature.3,4
Another possible explanation for the false-negative is
antibiotic pre-treatment. Administration of antibiotics
prior to obtaining an initial PCT has been shown to lead
to lower PCT values. 21 This patient was receiving
ertapenem for seven days prior to his admission. It is
presumable that if PCT is intended to indicate a systemic
response to an infection as the literature so far shows,
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then values should still be elevated if the microbial burden
has not been decreased enough so as to temper that
systemic response (e.g. poor source control, inadequate
duration of treatment, etc.).
An additional, yet equally important consideration, is that
this patient may not have been septic. At first, this seemed
to be unlikely given the magnitude of the Gram-negative
microbial burden evidenced in the patient’s abdomen.
Such anatomically disparate foci of infection (left
abdominal wall, left lower quadrant, right lower quadrant,
pre-vescicular) suggests there may have been a recent
seeding event in the context of long-term indwelling
central venous access. Given the highly virulent nature of
Klebsiella pneumoniae, it should have produced a robust
and clinically obvious systemic response.22 However, by
the current “Sepsis-3” diagnostic criteria utilizing the
sequential organ failure assessment (SOFA) score, the
patient may have not met criteria.23 Although he was
diagnosed with acute kidney injury based on a creatinine
of 1.0 mg/dL increased from a previously known 0.7 mg/
dL, it did not meet the SOFA criterion of 1.2 mg/dL.
Clinically, he appeared to be severely malnourished and
wasted in appearance, so a prior creatinine of 0.7 mg/dL
documented some weeks before the current admission
may still have been above his true baseline; there were no
other values documented. As such, he was considered to
have a true acute kidney injury, though it may not have
been due to sepsis. Determination of his baseline mental
status was confounded by his underlying Lewy body
dementia, making a Glasgow coma score SOFA criterion
impossible to reliably obtain. Significantly, he had none of
the typical hemodynamic changes classically associated
with sepsis. Finally, despite the perilous locations of the
patient’s abscesses, they may have been walled off to the
extent that they were effectively localized.
A final consideration is the patient’s many herbal
supplements as possible confounders. Herbal extracts
often contain numerous compounds in varying amounts
that may or may not be relevant to a given clinical
scenario. As an example, one study found that ursolic
acid, one of the compounds in bearberry leaf extract, was
able to ameliorate acute kidney injury associated with
sepsis in mice.24 A thorough review of the potential impact
of each of these supplements on the patient’s clinical
presentation is beyond the scope of this work.
False-positive PCT occurrences greatly outnumber those
of false-negatives. Christ-Crain and Muller have compiled
a list of common clinical scenarios.25 This list is adapted
from their article and presented in Table 1. It should be
noted that regarding the elimination of PCT, the renal
system does not appear to play a significant role,
therefore, acute kidney injury is not thought to produce
false-positives.26,27 Table 2 provides a summary of test
characteristics found across some of the larger studies
performed. Performance usually varies with the threshold
value studied.
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Table 1. Clinical scenarios that may produce false-positive or falsenegative PCT values. Adapted from Christ-Crain and Muller, 2005.25

Table 2. Selected published analyses of PCT sensitivity and specificity.3,28-32

CONCLUSION
Serum PCT can be a useful addition to the diagnostic
armamentarium in the evaluation of bacterial infection.
Similar to other biomarkers, it should not be solely relied
on or supplant clinical judgement. While false-positive
scenarios are more common, careful consideration must
be given to possible false-negative scenarios as this case
demonstrates. Testing may prove useful in cases of
clinical uncertainty and a PCT-guided algorithm may be a
beneficial addition to an established antimicrobial
stewardship program.

CURRENT FDA INDICATIONS FOR
TEST USAGE
The current FDA recommendation for usage of the test in
lower respiratory tract infections is strong discouragement
of antibiotics for PCT levels less than 0.1 ng/mL, discouragement for 0.1 to 0.25 ng/mL, recommendation for 0.25
to 0.5 ng/mL, and strong recommendation for levels
greater than 0.5 ng/mL. Additionally, the current FDA
recommendation for usage of the test in sepsis is discontinuation recommended if PCT is less than or equal to 0.5
ng/mL or if the PCT levels have decreased by greater than
80% from peak value.1
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LITERATURE REVIEW

Heart Failure with Preserved Ejection Fraction:
A Review of the ACC/AHA Guidelines and
Evidence-Based Management Strategy
Vikas Sunder, MD

INTRODUCTION
Heart failure with preserved ejection fraction (HFpEF) is
a clinical syndrome in which a patient has signs and
symptoms of heart failure including dyspnea, fatigue,
pulmonary rales, peripheral edema and an ejection
fraction greater than 50%. 1-4 Approximately half of
patients with heart failure have a preserved ejection
fraction.2-5 HFpEF is considered a distinct clinical entity
from other causes of heart failure with a preserved
ejection fraction such as valvular heart disease,
pericardial disease, and infiltrative cardiomyopathy.
HFpEF carries a poor prognosis, with an annual mortality
of 29% in patients discharged after an acute
decompensated heart failure admission.5 5-year survival
rates can be as poor as 50%.2 We know that patients
with HFpEF are more likely to be older, female, and have
hypertension. 3,4 Hypertension, in fact, is present in
80-90% of patients with HFpEF.3 The aim of this work is
to summarize current understanding of HFpEF and
review the latest ACC/AHA management guidelines
while highlighting studies which provide the evidence
for and against particular management strategies.

PATHOPHYSIOLOGY
The pathophysiologic mechanisms leading to HFpEF
are complex. One proposed pathway involves
understanding HFpEF within the context of a systemic
pro-inflammatory state. In HFpEF, it is the high
prevalence of co-morbid diseases such as obesity,
hypertension, and diabetes mellitus which leads to a
systemic pro-inflammatory state and causes coronary
microvascular endothelial inflammation. 6 This
inflammation leads to low protein kinase G activity in
the cardiomyocytes leading to hypo-phosphorylation of
titin favoring hypertrophy, high resting tension, and high
diastolic left ventricular stiffness.6 Decreased nitric oxide
bioavailability has also been implicated. 6 Diastolic
dysfunction can lead to elevated pulmonary venous
pressure, congestion, and symptoms of heart failure.
The presence of high diastolic filling pressure at rest or
with exertion is a hallmark of HFpEF.2 Asymptomatic
diastolic dysfunction without heart failure symptoms
carries an increased mortality, but is a separate entity
from HFpEF. 7 Heart failure with a reduced ejection
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fraction (HFrEF) is different in that it is driven by a loss of
cardiomyocytes and is characterized by ventricular
dilation.2,6 The presence of ventricular dilation is a key
factor distinguishing HFrEF from HFpEF.2

PHARMACOLOGIC MANAGEMENT
There have been numerous advances in the
pharmacologic management of HFrEF in the past 25
years related to blockade of the renin-angiotensinaldosterone system, beta blockade, neprilysin inhibition,
and even ventricular assist devices.2,3 Unfortunately,
most clinical trial data suggests that these modalities do
not alter the course of HFpEF or provide a reduction in
mortality. The 2013 ACC/AHA guideline for the
management of heart failure gives a class I recommendation that systolic and diastolic blood pressure be
controlled in patients with HFpEF.1 While control of
hypertension is therefore considered a mainstay in
management of HFpEF, there is currently no evidence
that reducing the systemic blood pressure improves
signs or symptoms of HFpEF. ACE inhibitors, ARBs,
along with beta-blockers, may be used to treat
hypertension in patients with HFpEF as a class IIa
recommendation in the ACC/AHA guideline. Data from
the ALLHAT trial showed that chlorthalidone could
reduce the incidence of new-onset HFpEF compared
with amlodipine and lisinopril, but this pertains to HFpEF
prevention rather than treatment.8 There is no evidence
in clinical studies that ACE inhibitors or ARBs improve
morbidity or mortality in patients with HFpEF. The data
is mixed with beta-blockers, with one recent metanalysis
showing no cardiovascular or all-cause mortality benefit
in patients with HFpEF. 9 Regarding aldosterone
antagonists, data from the TOPCAT trial showed that
patients treated with spironolactone had fewer hospitalizations for heart failure as compared to patients treated
with placebo, but that spironolactone did not reduce
total deaths or hospitalizations from any cause during
the study.10 The ACC/AHA gives a class IIb recommendation for the use of aldosterone antagonists like
spironolactone to decrease hospitalizations in HFpEF.1
Statins have been shown to be beneficial in some
studies. One Swedish study found that patients with
HFpEF had a one-year survival of 85% when they were

treated with statins versus 80% when not treated with
statins.11 More recently, given that impairment in nitric
oxide signaling has been implicated in the pathophysiology of HFpEF, as introduced above, investigators in
the INDIE-HFpEF trial tested the use of inhaled inorganic
nitrite delivered via a micro-nebulizer versus placebo
over a 4-week period. The patients who received the
inhaled inorganic nitrate did not demonstrate a
statistically significant improved exercise capacity.12

SYMPTOM-BASED MANAGEMENT AND
QUALITY OF LIFE
The only intervention which has consistently been
shown to improve quality of life in patients with HFpEF
as assessed by the Minnesota Living with Heart Failure
Questionnaire is exercise. 13 Referring patients to a
cardiac rehabilitation program can improve exercise
capacity.13 Weight loss can also be beneficial in obese
patients as caloric restriction has already been shown to
improve exercise capacity in patients with HFpEF.14
Maintenance of fluid balance is a pivotal part of symptom
based management of HFpEF. The 2013 ACC/AHA
guideline for the management of heart failure gives a
class I recommendation that diuretics should be used
for relief of volume overload in patients with HFpEF. 1
This recommendation is based off findings from the
CHAMPION trial in which patients had pulmonary artery
monitors implanted to monitor their hemodynamics
and providers made medication adjustments based on
this primary data.15 A number of changes were made to
diuretic medications and these patients had a reduction
in heart failure related admissions at 6 months.15

MANAGEMENT OF ATRIAL FIBRILLATION
Atrial fibrillation is very common in patients with HFpEF,
and occurs in approximately two-thirds of patients
according to a community- based study in Olmstead
County, Minnesota.16 Supraventricular arrhythmias like
atrial fibrillation and associated tachycardia are
dangerous for patients with HFpEF in that they impair
atrial contraction and diastolic filling time. Patients with
HFpEF and atrial fibrillation have an increased mortality.16
The 2013 ACC/AHA guideline recommends
management of atrial fibrillation according to published
clinical practice guidelines in patients with HFpEF which
includes either a rate control or rhythm control strategy.1

MANAGEMENT OF CORONARY
ARTERY DISEASE
Approximately two-thirds of patients with HFpEF have
coronary artery disease demonstrated by coronary
angiography.17 Patients with HFpEF and coronary artery

disease have a higher mortality.17 Revascularization of all
coronary stenoses greater than 50%, that is, complete
revascularization, may be associated with improved
outcomes in these patients. One study found that
patients with HFpEF and coronary disease who underwent
complete revascularization had less reduction in ejection
fraction at four-year follow-up echocardiography.
Furthermore, patients who underwent complete
re-vascularization by percutaneous intervention or
bypass grafting survived longer than those patients who
underwent incomplete revascularization or had no
revascularization performed. 17 Further prospective
research is needed to determine optimal management
of coronary artery disease in HFpEF. Patients with HFpEF
who have angina can be treated symptomatically with
beta-blockers or calcium channel blockers.

CONCLUSION
Optimal management of HFpEF remains unclear even
as its prevalence and economic burden continue to
increase. 2-5 Further prospective trials enrolling this
population of patients are needed. Patients with HFpEF
represent a heterogenous group and there may not be
a “one-size fit all” type of treatment, and this is likely not
the best strategy. The latest ACC/AHA guideline for
management of heart failure published in 2013
recommends symptomatic management with diuretics
and control of co-morbid disease, including
hypertension and atrial fibrillation. The evidence clearly
supports the use of exercise in patients with HFpEF to
both improve quality of life and increase exercise
capacity. Further study is needed regarding the optimal
amount and form of exercise which could be beneficial.
Spironolactone may be used in patients with HFpEF to
reduce hospitalizations related to heart failure.

KEY POINTS
1. The latest ACC/AHA guideline for management of
heart failure provides a class I recommendation that
the systolic and diastolic blood pressure be controlled
in HFpEF and that diuretics be used for relief of
volume overload.
2. Exercise is the only intervention which has been
shown to improve quality of life in patients with
HFpEF. Patients with HFpEF should be referred to a
cardiac rehabilitation program.
3. Aldosterone antagonists may be considered to
reduce future hospitalizations related to heart failure
based on current evidence.
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CREATIVE WRITING

To Those Who Don The White Coat
Cuckoo Choudhary, MD

Don’t lose your idealism
At least, don’t let it be snatched
If at all it seems at some point that you have to lose it, drag the process along
Let it be slow, cling on to what you believe in
Your road will be tough
You may not be able to “attain” certain things, but you will certainly achieve
Remember that your coat stands for
Responsibility
Hard work
Display of warmth and affection
Patience
Putting others before your own self
Believing that holding a person’s hand is the most important thing in the world when they are scared
Hoping even when there is no hope
And at times, not speaking the bare "truth" without lying
Continuing to believe that one person can make a difference in this world
A small difference may be, albeit a difference
But above all, remind yourself that your white coat stands for privilege
Yes, the privilege to study the art and science of medicine, and to use it everyday
It is a privilege to know the privileged information of fellow human beings
Respect that privilege
And then, and only then, will the "white coat" respect you!
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CREATIVE WRITING

No Hard Feelings
Colin Thomas, MD

“Do you understand what I’m telling you?” This time I squeezed Sam’s hand even harder. I suppose we’ll call
our patient Sam for the extent of this story; this of course wasn’t his real name, but his name isn’t exactly the
point. The pH of Sam’s blood was dangerously low and the pCO2 of his blood was critically high. It was 1:37AM
and I had just told Sam that if we didn’t place him on BIPAP, or even consider intubating him, then I didn’t think
he would live through the morning.
“I first met my wife in 1960 when I was stationed in Germany for the Army. She didn’t speak English and I didn’t
speak German. If we had spoken the same language at the time [he chuckled], we probably wouldn’t had fallen
in love. We were such different people…” The shards of telemetry alarms and nervous chatter of the rapid
response team rattled in my ears when he spoke this; however, the serene cadence of Sam’s voice and look in
his eyes (in retrospect, I think it was his eyes most of all) slowly tuned the panic in my ears into a muffled…
hum: a white noise.
“Now I won’t let that beard or that white-coat fool me… I know you’re just a kid...” I’ll mention Sam’s eyes once
more, because it’s something I find myself thinking about from time to time; that is, what exactly it was that
they conveyed—maybe it was confidence, it’s difficult to say. But, it was the oddest thing… for a brief flicker of
time during the endurance sprint of a night shift, I had one of the most genuine human experiences of my life
with a man I had just met eight minutes prior.
“Doc… I’m not exactly sure where I’m going to go from here, but my body isn’t holding onto me anymore…
you know, you always wonder if you’ll be ready…” Sam’s breaths were short and stiff as he said this,
“…We’re herded our entire life by cold and angry feelings…but, you know, in the end… you’ve got to
understand that I have none of those…”
“And what are those, Sam?”
“Hard feelings,” Sam said with a soft smile.
Looking at Sam, I saw every piece of him—decades of growth and recycled parts, fading grayer and more
wrinkled with the passing of each milestone. It was aging—the accumulation of nature’s tax on our body’s
self-sustained existence. I imagined Sam’s childhood, his parents and grandparents. I imagined his fears and
regrets and I imagined what eighty-nine years of both heartbreak and joy must be like.
I later heard that Sam passed away soon after on comfort-care, looked upon by many tearful eyes of friends
and family. I had left his room after our conversation together to respond to another page for another patient.
On the speedy walk there, I began to eat the granola bar in my white-coat pocket as I passed through the
bridge between the Gibbon and Pavilion buildings. I could see the Philadelphia night through the glass, abstract
in its enormity (and alienating by its abstraction, I suppose) and lit by the automated street lights, programed
to turn on and off at specific times of the night, but also a handful of lights in apartment windows and offices;
and, pausing, I thought… how beautiful the latter is.
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